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ABSTRACT 
 
Several 6-aryl-9-benzylpurines have been shown to be selective antagonists for various 
adenosine receptors including A1, A2A, A2B and A3. The structures of the most active 
compounds resemble those screened in the Mycobacterium tuberculosis (Mtb) project in 
our group (Figure A).  Some of these compounds were also screened for the adenosine 
receptors. The results from this screening and the exploration of  structure-activity 
relationship (SAR) made the foundation for synthesizing new purine analogous as 
selective adenosine receptor antagonist. The target compounds were successfully 
synthesized with Stille and Suzuki coupling reactions and new effective methods have 
been developed.  Herein the chemistry will be discussed.    
 
 
    
Figure A. Structure of target compounds. R1 = Cl or NH2. R2 = F or Cl.     
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ABBREVIATIONS 
 
AR Adenosine receptor 
Ac2O Acetic anhydride 
BBB Blood-brain barrier 
Bu  Butyl 
CNS Central nervous system 
COPD Chronic obstructive pulmonary disease 
cAMP Cyclic nucleotide adenosine 3’,5’-monophosphate 
DA Dopamine 
DMF Dimethylformamide 
DCM  Dichloromethane 
DMSO  Dimethyl sulfoxide 
DMA  Dimethylacetamide 
EWG Electron withdrawing group 
EDG Electron donating group 
EtOAc  Ethyl acetate 
EtOH  Ethanol 
GPCR G-protein coupled receptors 
GDP Guanine diphosphate 
GTP Guanine triphosphate 
HMQC  Heteronuclear Multiple Quantum Coherence experiment 
HMBC  Heteronuclear Multiple Bond Correlation experiment 
IUPAC International union of pure and applied chemistry 
KF Potassium fluoride  
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Mtb Mycobacterium tuberculosis 
MS Multiple sclerosis 
Me  Methyl 
MeOH  methanol 
MS  mass spectroscopy 
NMR  Nuclear magnetic resonance 
n.d  not tested/ not determined  
PD Parkinson’s Disease 
PDE Phosphodiesterase enzyme 
r.t.  room temperature 
SAR Structure-activity relationship 
THF  Tetrahydrofuran 
TLC    Thin Layer Chromatography 
UV  Ultraviolet light 
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1. INTRODUCTION 
 
“History suggests drug discovery is art as well as science”.1 During our time on this 
earth we have been using nature to cure illness. Ancient civilizations of Hindus, Chinese, 
Mayans of Central America and the Mediterranean people of antiquity hold the oldest 
records for the use of therapeutic plants and minerals.2 Drug discoveries have a long 
tradition. Only the method and efficiency have changed. To design, synthesize and 
develop drugs is a long process. Considering the number of diseases without any specific 
drugs it is becoming more important to develop new chemical entities suitable for 
therapeutic use. Since the end of the nineteenth century countless drugs have been 
synthesized. The main reason for this was the progress in organic chemistry, which gave 
way for the pharmaceutical industry to bloom. Many peoples’ lives have been saved and 
we have also extended our living time: “The unprecedented increase in human life 
expectancy, which has almost doubled in a hundred years, is mainly due to drugs and to 
those who discovered them.” 2  
 
New drug discoveries require a considerable element of luck alongside with hard work. 
In this game where stakes are high, we are constantly seeking ways of improving our 
odds of being lucky in drug design. The first step is to look at the structure-activity 
relationship (SAR) 2 of the paharmacophore (recognition and binding geometries) and 
find potential lead compounds, which is a chemical structure that serve as a starting point 
for further chemical modification.2 Good lead compounds have high potency2, high 
selectivity2, best pharmacokinetics 3 and are least toxic towards the normal cells in our 
body. In the course of evolution, several “designs” have emerged as preferred templates 
for certain functions. Just as the development of wings proved to be suited for flying, 
proteins and their ligands have evolved to perform specific biological functions.1 By 
understanding these underlying principles, the drug-receptor interaction theory was 
evolved by John Newport Langley and later improved by Paul Ehrlich.4  
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1.1. THE BIOLOGIAL CONNECTION 
~DRUG AND RECEPTOR 
 
1.1.1 Receptor theory 
A receptor is a molecular structure or site on the surface or interior of a cell that binds 
with substance such as hormones, neurotransmitters or drugs.3 Receptors have many 
different functions in our body such as muscle contraction, regulation of growth factor, 
alternation of cellular morphology or function and gene activation.2,5  Processes that lead 
to successful binding are generally called molecular recognition.6 There are four major 
families of receptors that drugs are able to interact with. One of them is G-protein 
coupled receptors (GPCR). A1, A2A, A2B and A3 are adenosine receptor (AR) subtypes of 
the GPCR family.2 They can be stimulated by potential drugs that work as an agonist or 
an antagonist (Figure 1). The potential of adenosine receptors as drug target was first 
reviewed in 1982.7  
 
 
Figure 1. Agonist- binding lead to a certain biological response in the cell. Antagonist- 
inactivation of the receptor. No biological response.  
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1.1.2  Adenosine and the structure of G-protein coupled receptor  
Adenosine (1) (Figure 2) is a ubiquitous purine ribonucleoside that exists in all cells, 
where it has important regulatory functions. It is a signalling substance, which mediates 
its effect by the activation of four receptor subtypes (A1, A2A, A2B and A3). All of them are 
members of the Class A, (rhodospin-like) family of the G-protein-coupled receptors 
(GPCR).8 The estimated number of GPCR in human genome is ~30000 and this 
corresponds to more than 3% of the total number of genes.9 They are large membrane 
bound proteins, which transduce their signal via the activation of an intracellular guanine 
nucleotide-binding protein (G protein). This family of proteins has seven hydrophobic 
domains that span the plasma membrane and possess alpha helical secondary structure 
(Figure 2).2  
 
The extracellular region of the protein is composed of the N-terminus and three 
extracellular loops, which contain the ligand-binding site. The intracellular regions of the 
protein comprise the C-terminus and similarly three intracellular loops. The cytoplasmic 
side also includes the binding site of the G protein.2,7 It should be noted that generally the 
transmembrane helices of the GPCR are uniform in size (20-27 residue), but their N- and 
C-terminal segments and the loops connecting their transmembrane helices vary widely 
in length with the identity of the GPCR (7-595 residue for the N- and C-terminus and 5-
230 residue for the loops).9 Structure of A1 receptor and the possible interaction with 
adenosine is illustrated in Figure 2.10    
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Figure 2.9,10 Model of the A1 adenosine receptor and adenosine (1). The seven 
transmembrane helices (I through VII) are arranged in a counter clockwise orientation. 
 
1.1.3 The mechanism of G-protein coupled receptor 
Generally the ARs are classified as inhibitors or activators of adenylyl cyclase activity. 
Usually the stimulation  begins through binding of a ligand to a G protein-coupled 
receptor.9 A schematic presentation of adenylyl cyclase activation via GPCR is shown in 
Figure 3.11  The binding triggers adenylyl cyclase to synthesize cyclic nucleotide 
adenosine 3’,5’-monophosphate (cAMP), which plays critical roles in mediating cellular 
signals in response to hormones, neurotransmitters, chemokines, and cytokines. The 
newly synthesized cAMP nucleotide binds and activates effectors, such as protein kinase 
11 
 
 
 
A. The protein kinase phosphorylates variety of substrates, like ion channels and 
transcription factors. The resulting signal can lead to changes in gene expression and cell 
metabolism. This will further lead to regulation of a wide variety of cellular functions. 
Some of them are immune responses, cardiac and smooth muscle contraction, visual 
response, apoptosis and growth control.2 
 
AgonistGPCR
GDP
α β γ
G-protein
(sub units α,β and γ)
Unit α bound to GDP
(a)
β γ
(b)
GDP
α
ATP cAMP
Further responce via activation of
protein kinases and phosphorylatio
of proteins  
Figure 3.11 Stimulation of adenylyl cyclase via G-protein coupled receptor (GPCR, 
green); (a) agonist approaching GPCR, guanine diphosphate (GDP) is bound to α-subunit 
of G-protein; (b) Binding of agonist to GPCR  results in an exchange of GDP with 
guanine triphosphate (GTP). GTP + α-subunit moves to adenylyl cyclase (red) and 
stimulates the enzyme. 
 
1.1.4  Xanthine antagonist for the adenosine receptors  
Adenosine is  unstable and has a small half life (t1/2 <10s). Therefore, its application as a 
drug is limited, but it is used in certain heart diseases.8 Xanthines were the first class of 
adenosine antagonist to be investigated and also the greatest explored.12   Alkylxanthines 
are adenosine antagonists, which stimulate the activity of the central nervous system 
(CNS) and have been proven to be effective as cognition enhancers. This action leads to 
increased cerebral blood flow, that in turn increases glucose and oxygen availability to 
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the brain.7 A naturally occurring class is metylxanthines, found in coffee (coffea 
Arabica), cacao (Theobroma cacao)  and tea (camellia sinensis). The most important of 
them are caffeine and theophylline and they differ only by the position and number of 
methyl group on their xanthine ring system (Figure 4).2  
 
 
N
N N
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R3
8
9
6
3
5 7
2
1
4
 
 
 R1 R2 R3 
Caffeine CH3 CH3 CH3 
Theophylline CH3 CH3 H 
 
Figure 4.2 Structure difference between the methylxanthines. The numbers indicate the 
numbering system for purine. 
 
Caffeine and theophylline is classical nonselective xanthine antagonist and display 
micromolar affinity for the AR subtypes. Caffeine is added to cola drinks as well as to 
pain stimulators. Theophylline is used as a bronchodilator in the treatment of asthma and 
chronic obstructive pulmonary disease (COPD). The bronchodilation is believed to occur 
through inhibition of the enzyme phosphodiesterase (PDE).8 It has recently been shown 
that theophylline does inhibit PDEs in vitro, and x-ray crystallographic studies have 
identified the binding residues that interact with the methylxanthines (Figure 5). 
Theophylline binds to the active site (subpocket) via hydrophobic bonds. It seems like 
theophylline is sandwiched between a phenylalanine and a valine. Its binding affinity is 
strengthened by hydrogen-bonding between a tyrosine and N-7, and a glutamate and O-6 
of the xanthine ring system.2,13           
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Figure 5.2 Theophylline interactions in the catalytic pocket of PDE. 
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1.2 THE VARIOUS ADENOSINE RECEPTORS AND THEIR FUNCTION 
~DETAILED DESCRIPTION  
 
The stimulation by the binding of an agonist will lead to various intracellular responses. 
It is well known that more than one adenosine receptor can be expressed in a singe cell 
and this could lead to an atypical pharmacological response.14 The distribution of the 
adenosine receptors in the body are show in Table 1.7 There are many different diseases 
connected to each adenosine receptor subtype. Inflammatory conditions, sepsis, heart 
attack, ischemia-reperfusion injury, vascular injury, spinal cord injury, chronic 
obstructive pulmonary disease (COPD), asthma, diabetes, obesity, inflammatory bowel 
disease, retinopathy, and Parkinson’s Disease (PD) are just a few examples.8 New 
developments in medicinal chemistry for these receptors have enabled researchers to 
identify potential therapeutic areas for drug development.  
 
Table 1.7  Tissue distribution of adenosine receptor subtypes.   
Adenosine 
receptor 
A1 A2A A2B A3 
Tissue 
Distribution 
-Brain (cortex, 
hippocampus, 
cerebellum, 
thalamus)  
-Spinal cord  
-Testis  
-White adipose 
tissue,    
-Heart  
-Kidney 
-Brain (striatum, 
nucleus 
accumbens, 
tuberculum 
olfactorium)  
-Heart  
-Lungs thymus  
-Spleen,  
-White adipose 
tissue 
-Pars tuberalis 
(pituitary gland) 
-Large intestine  
-Bladder 
- Blood vessels 
Species 
dependent; 
Human:  
-Lung  
-Liver  
-Placenta  
-Brain  
-Aorta  
-Kidney  
-Heart  
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1.2.1  Adenosine A1 receptor ligands  
The A1 receptor is the best known and most studied AR subtype.15 It is most concentrated 
in the brain,16,17 but is also present in other tissues as well (see table 1). It is therefore 
essential that compounds targeted for A1 is able to cross the blood-brain barrier (BBB).12 
Some of the diseases connected to A1 receptor are asthma, inflammation, heart failure, 
hypertension and renal failure (kidney). Important classes of A1-selective antagonist 
comprise xanthine derivates with bulky C-8 substituent and/or carrying a bulky 
substituent at N-6. Low water solubility of many A1 antagonists remains a problem. 
Recent developments include the introduction of polar functions to increase the water 
solubility for an example, compound SW-13 (2).15 Compounds N-0860 (3) and KW-3902 
(4) are undergoing phase III development as agents for heart failure (Figure 6).8  
 
 
Figure 6. Selective A1 antagonists. 
 
1.2.2  Adenosine A2A receptor ligands   
Ischemia (blood supply), wound healing, sleep inducers, glaucoma (nerve) and Parkinson 
disease (PD) are some of the diseases connected to A2A receptor. Dopamine (DA) 
modulates motor coordination and fine movements in our body.18 Activation of the A2A 
receptor in parts of the brain decreases the affinity of dopamine D2 receptors for DA. 
Therefore there has been done extensive research in the last 10 years to develop potential 
drugs for treatment of PD and other neurodegenerative disorders.8,14 Most of these 
compounds are chemically 8-styrylxanthines, like KW-6002 (5), currently in phase III for 
16 
 
 
 
PD treatment, has specific antagonist effect.18,19 Pyrazolo[4,3-e][1,2,4]triazolo[1,5-
c]pyrimidines like SCH-420814 (6), in phase II (Figure 7).8  It has also been found that 6-
(2-furanyl)-9H-purine-2-amine derivatives have high A2A receptor antagonist affinity. 
Benzyl substituent at N-9 with two fluorine atoms or a combination of fluorine and 
trifluoromethyl produce the best potency and selectivity (7-9) (Figure 7).20 Similarly 6-
aryl-9H-purin-9-ylcarboxamides derivates demonstrate high potency and selectivity 
towards A2B. Compound 10 is an example.21     
 
N
N N
N
H2N
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O
N N
N
N O
NH2
N
NNNO
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N
N N
N
O
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O
O
N
N N
N
O
H2N
R1
R5
R2
R3
R4
7: R1 = R5 = F
8: R2 = F, R3 = CF3
9: R3 = CF3, R5 = F
10
 
Figure 7. Selective A2A antagonists.  
 
1.2.3  Adenosine A2B receptor ligands  
The adenosine A2B receptor is the least well characterized of the four adenosine subtypes, 
due to the lack of selective agonist and antagonist.7,22 It was distinguished from A2A due 
to its much lower affinity for adenosine. Adenosine is increased under abnormal 
conditions like under chronic pulmonary diseases, asthma, bowel diseases (intestine) 23 
and other conditions. Selective A2B are mostly xanthine derivates with substitution on the 
8-position. A series of 8-pyrazole xanthine compounds have been found as selective A2B 
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antagonist. One of them is CVT-6883 (11) and it is undergoing phase I development for 
treatment of asthma (Figure 8).8 Further research has shown that 3-benzamide purine 
derivates like compound 12 has excellent A2B affinity and good selectivity.24  
 
 
Figure 8. Selective A2B antagonists. 
 
1.2.4  Adenosine A3 receptor ligands  
A3 adenosine receptors are the most recently discovered among adenosine receptors.14 
The A3 AR is involved in many disease pathways like cancer, cardiac hypoxia, allergic 
conditions and Multiple sclerosis (MS). Natural antagonists such as caffeine and 
theophylline, show in general low affinity for A3. Human A3 selectivity is also found for 
several other classes of heterocycles like, xanthines, pyridines, flavonoids, thiazoles, 
thiadiazoles, isoquinolines and quinazolines.8,25  There is a huge species difference in A3 
receptor binding affinity for xanthine antagonist.7 1-Benzyl-3-propyl-1H,8H-
imidazole[2,1-f]purine-2,4-diones (13) is a highly potent and selective A3 antagonist. 
Cyclization was made between the 7- and 8-position of the xanthine core (Figure 9). No 
selective A3 ligand is currently undergoing clinical trials, but A3 antagonist have been 
patented as inhibitors of tumor growth: MRE-3008-F20 (14) (Figure 9).8  
 
18 
 
 
 
 
 
Figure 9. Selective A3 antagonists. 
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1.3  DRUG DESIGN  
 
1.3.1 Target molecules 
The A2A antagonist SCH 58261 15 (Figure 10) has been reported to display nanomolar 
potency and modest selectivity (A2A Ki = 4.3 nM, A1/A2A = 35).20 Biological data in this 
thesis is presented as Ki values which is the dissociation constant for inhibitor binding.26 
The smaller value for Ki the better is the compound as inhibitor for adenosine receptors. 
Because of its low selectivity and poor solubility it has been used as a lead compound 
(15) in structure-activity relationship (SAR) investigation to find better target molecules. 
In compound 16, the tricyclic core in SCH 58261 is replaced by purine ring, still carrying 
an amino-, a 2-furyl and an arylalkyl group. Several compounds 16 with different 
arylalkyl groups have been identified with high A2A receptor antagonist affinity.20  
 
 
Figure 10.11 Structural relationships between A2A antagonists and antimycobacterial 
compounds.  
 
Compounds 16 are chemically closely related to 6-aryl-9-benzylpurines examined in our 
group as selective inhibitors for Mycobacterium tuberculosis (Mtb) in vitro.27-36 Some of 
the most active antimycobacterial (17) are shown in Figure 10. The 6-aryl-9-
benzylpurines developed in the antimycobacterial project in general display very low 
toxicity towards mammalian cells.27-33 Therefore, a series of compounds 18 initially 
20 
 
 
 
prepared in the project directed towards antimycobacterial, have been screened as 
potential ligands for the four adenosine receptor subtypes. The screening has been carried 
out in the group of Professor Christa Müller at the University of Bonn. Approximately 60 
target molecules of compound 18 have been screened and the result is the basis for the 
structures chosen as synthetic targets in this thesis. Table 2 gives an overview of some of 
the compounds that are significant in this thesis.11    
 
Table 2.11 Target molecules of compound 18 (Figure 10). 
Nr. R2 R9 Ki (µM) or % inhibition at 10 µM value.   
A1 rat 
[3H]CCPA 
A1 human 
[3H]CCPA 
A2A rat 
[3H]MSX-
2 
A2A 
human 
[3H]MS
X-2 
A2B 
human 
(% 
inhib. at 
1 µM)  
A3 
human 
[3H]PS
B-11 
18a -H 
 
> 10 
(25 ± 1) 
n.d  2.95 ± 
0.81 
n.d  > 1 
(7 ± 2) 
> 10 
(28 ± 3) 
18b -H 
 
> 10 
(12 ± 1) 
n.d  > 10 
(37 ± 1) 
n.d  > 1 
(24 ± 1) 
> 10 
(32 ± 4) 
18c -H 
 
> 10 
(22 ± 3) 
n.d  6.67 ± 
1.17 
n.d  > 1 
(16 ± 4) 
> 10 
(27 ± 2) 
18d -H 
 
> 10 
(27 ± 6) 
n.d  1.28 ± 
0.14 
n.d  ≥ 1 
(47 ± 1) 
12.7 ± 
0.7 
18e -H 
 
> 10 
(35 ± 2) 
n.d  2.59 ± 
0.93 
n.d  >> 1 
(0) 
Ca. 10 
(49 ± 1) 
21 
 
 
 
18f -H 
 
> 10 
(42 ± 4) 
> 10 
(25 ± 6) 
0.342 ± 
0.088 
0.302 ± 
0.051 
Ca. 1 
(47 ± 2) 
6.69 ± 
1.18 
18g -H 
 
> 10 
(10 ± 1) 
≥ 10 
(48 ± 3) 
0.443 ± 
0.088 
0.537 ± 
0.036 
 
> 1 
(23 ± 3) 
2.11 ± 
0.78 
18h -H 
 
> 10 
(16 ± 0) 
n.d  Ca. 10 
(49 ± 0) 
n.d  > 1 
(10 ± 2) 
2.98 ± 
0.58 
18i -H 
 
≥ 10 
(40 ± 5) 
n.d  6.11 ± 
1.69 
n.d  > 1 
(21 ± 0) 
≥ 10 
(48 ± 1) 
18j -Cl 
 
> 10 
(39 ± 4) 
> 10 
(45 ± 6) 
> 10 
(34 ± 4) 
1.74 ± 
0.22 
> 1 
(1 ± 3) 
0.80 ± 
0.215 
18k -Cl 
 
> 10 
(10 ± 2) 
n.d  > 10 
(25 ± 6) 
n.d  > 1 
(24 ± 2) 
3.69 ± 
1.25 
18l -Cl 
 
> 10 
(39 ± 2) 
n.d  2.199 ± 
0.532 
n.d    
18m -Cl 
 
> 10 
(12 ± 2) 
n.d  > 10 
(22 ± 2) 
n.d  > 1 
(17 ± 3) 
1.12 ± 
0.16 
18n -NH2 
 
0.997 ± 
0.253 
n.d  0.111 ± 
0.020 
n.d  0.315 ± 
0.039 
2.90 ± 
0.25 
18o -NH2 
 
1.360 ± 
0.190 
n.d  0.138 ± 
0.037 
n.d  n.d  n.d  
22 
 
 
 
18p 
new 
-NHCOMe 
 
1.11 ± 
0.19 
5.92 ± 
0.37 
0.264 ± 
0.067 
0.089 ± 
0.011 
0.0111 
± 0.012 
0.0703 
± 
0.0249 
18q 
new 
-NHCOMe 
 
1.510 ± 
0.120 
n.d 0.321 ± 
0.069 
n.d  n.d  n.d  
18r 
new 
-N(COMe)2 
 
1.73 ± 
0.09 
> 10 
(26 ± 8) 
1.24 ± 
0.295 
0.677 ± 
0.11 
≥ 1 
(44 ± 4) 
0.205 ± 
0.008 
18s 
new 
-N(COMe)2 
 
0.417 ± 
0.030 
n.d 0.247 ± 
0.030 
n.d  n.d  n.d  
 
 
The potency and the selectivity for the adenosine receptors is dependent on whether there 
is an electron withdrawing group (EWG), electron donating group (EDG) or a 
combination of both on R2 (18a-18s). A phenyl ring is required at R9 (18a-18s) and 
potency and selectivity is influenced by the position (ortho, para and meta) and the 
number of halogens on the aromatic ring. 
 
From table 2 it is possible to describe some of the important chemical features that are 
essential for good selectivity and potency for the various ARs:  
- A1 AR:  A1 has poor potency until an EDG group or a combination of EWG/EDG 
is introduced at R2. Diacetamide on R2 and fluoride(s) on ortho position on phenyl 
are required. Compound 18s has the best potency, but a very poor selectivity 
compared to A2A. Fluorides on the phenyl ring are appreciated in the A1 receptor 
binding pocket, because when they are removed the total affinity drops by 1.31 
µM (18r & 18s).      
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- A2A AR: Several compounds show good potency for A2A with EWD on R2, but 
better potency is received when amino, acetamide or diacetamide is introduced 
(EDG or EWD & EDG). The difference between acetamide and diacetamide is 
huge for A2A human receptor (18p & 18r).  Compound 18n display the best 
potency and selectivity compared to A1, A2B and A3. For A2A human receptor, 
chlorides are evidently less appreciated than fluorides (18f & 18g). This indicates 
a strong electron donating amino acid residue in the receptor sup pocket. The 
fluoride will function as a hydrogen-bond acceptor.      
   
- A2B AR: A EWG group like amino or combination of EWG and EDG like 
acetamide is required on R2. This is similar to the A1 AR. Acetamide at R2 gives a 
much higher affinity for A2B receptor, compared to amino (18n & 18p). 
Compound 18p show the best potency and selectivity compared to A1, A2A and 
A3. 
 
-  A3 AR: Compound 18j with a EWG (-Cl) at R2 has the best selectivity and good 
potency compared to the other AR antagonists. But 18p has the best potency, but 
poor selectivity compared to A2B AR. Affinity for the other receptors increases 
when R2 has EDG or a combination of EWG and EWG. Despite this, acetamide 
on R2 has 64% more affinity for A2B AR, compared to the diacetylated antagonist 
(18p & 18r). Chlorides seem to be more accepted on the aromatic ring compared 
to fluorides (18f & 18g). This is opposed for A2A human receptor.       
 
Even though some of the data, were the halogen are attached to phenyl, is missing for 
A2A -, A2B -, A3 AR, it seems like the halogens have a key role in the binding geometry 
for the AR antagonist (table 2). AR compounds (18a-18s) generally gain better 
affinity when fluoride(s) is present, compared to chloride(s). It is well known that 
fluorides are used to further improve the physico-chemical properties of potential 
drugs, often with dramatic impact on biological properties. It has been estimated that 
up to 20% of new drugs released contain fluoride.37       
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1.4  THE CHEMISTRY  
 
All starting materials were prepared by N-alkylation of purines.  Stille and Suzuki 
coupling are the methods applied for introducing C-C bond on the N- alkylated purines 6-
position. Some of these compounds have further been subjected to acetylation.      
 
1.4.1  Purine chemistry   
Purine (19) is the most abundant nitrogen-containing heterocycle on earth (Figure 11).38 It 
is a colourless, crystalline compound which is characterized as a weak base.39 Most of the 
naturally occurring purines have at least oxygen or nitrogen incorporated in the ring 
system. Purine itself is not found in nature, and was first prepared by Emil Fischer,39 but 
the bicyclic ring system is found in many naturally occurring compounds with a wide 
range of biological roles.38  
 
 
 
Figure 11. The name purine goes back to the Latin words purum (pure) and uricum 
(urine).39 Herein the purines will be numbered according to this model, following the 
IUPAC convention.  
 
In principle purines can exist in four different tautomers containing NH-hydrogen 
(Scheme 1). According to quantum mechanical calculation, the 1H- and the 3H-tautomers 
are much less stabile than the other two isomers.39 The most significant are 7H- and 9H-
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tautomers. They are present in solutions and the tautomer distribution is dependent on the 
nature of solution and temperature.40 
 
Scheme 1. Purine tautomers.   
 
Purines bicyclic ring system has 10 π-electrons and composes a 5- and 6-ring. The 6-ring 
is derived from pyrimidine (20) and the 5-ring from imidazole (21) (Figure 11).40 
Pyrimidine can be compared to benzene in certain chemical properties. Both molecules 
have 6 π-electrons. Benzene has an even distribution of electrons, whereas pyrimidine has 
electron deficient carbons due to higher electron negativity of the nitrogens, and the 
carbons will easily undergo nucleophilic substitution. 41 If the pyrimidine part on the 
purine has a good leaving group (e.g. a halogen) the molecule will be considerably more 
reactive. The imidazole ring has 6 π-electrons distributed in a 5-ring. Because of this high 
electron density, electrophilic aromatic substitutions will rather occur on the imidazole 
ring. As a result of purines fused chemistry, nucleophilic substitutions can take place on 
both rings, while electrophilic substitutions can only be done on the 5-ring.40    
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1.4.2  N-alkylation 
In N-alkylation a chemical entity is substituted on the purine heteroatom (Scheme 2). The 
substituent used herein is benzyl derivate with flour or chloride.    
          
 
 
Scheme 2. N-alkylation of 6-chloropurine, Y = Cl or NH2; (a) B = K2CO3. The base 
removes hydrogen and resonance structures of two anions are formed; (b) R = benzyl 
derivate with flour or chloride. The alkyl halide (R-Cl) react and to isomers are formed.  
 
A lot of starting materials were synthesized early in our group utilised N-alkylation 
reaction with purine27-33,42-44 and they normally give two isomers. It is not possible to 
achieve complete selectivity. Substituent on purine has an effect on the isomer 
distribution in a way that the N-9-alkylation is formed in highest yield and is the main 
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product. Chloride is good leaving group and the isomers are separated by flash 
chromatography.45 The N-9-alkylated product is further subjected to Stille or Suzuki 
coupling.  
 
1.4.3  Coupling reactions: in general  
Cross-coupling reactions are widely used and efficient way of constructing C-C bonds. 
Treatment of purines containing suitable leaving groups (halogen) with diverse type of 
organometallic compounds like Mg, Cu, Al, Zn, Sn and B has been extensively studied 
and several efficient preparative methods for the synthesis of various types of 2-, 6-, and 
8-C-C-purines have been developed.27,46 The order of reactivity of aryl halide in 
palladium mediated cross coupling reactions is found to be Ar-I > Ar-Br >> Ar-Cl. 6-
chloropurines (Scheme 2) have earlier in our group shown to be reactive enough to give 
high yields of coupling products in palladium catalyzed  reactions. In addition 
iodopurines are less commercially available.33 For these reasons 6-chloropurines was 
chosen. The Suzuki reaction is, together with the Stille reaction, currently the most 
popular method for the introduction of aryl or heteroaryl substituent in the purine 2-, 6-, 
or 8-position. The choice of method is often governed by the availability of the desired 
organometallic coupling partner. The Suzuki coupling may be regarded as more 
environmentally friendly, compared to the Stille coupling were organotin compounds are 
employed (Scheme 5).38 
 
1.4.4  Stille coupling  
The stille reaction has established itself as one of the most general and most selective 
palladium-catalyzed cross-couplings reactions.47 In 1978 John K. Stille and his co-
workers carried out extensive synthetic and mechanistic work that made this reaction a 
standard method in organic synthesis. The Stille reaction rank today as the more general 
transformations in organic synthesis. Stille coupling is used in synthesizing complex 
molecules and it display high selectivity and broad scope. In addition Stille coupling has 
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a good tolerance toward most functional groups. This makes it particularly effective for 
transformation of highly functionalized molecules. The main advantage is that sp, sp2 and 
sp3 hybridized carbons can be coupled for the formation of a C-C bond (Scheme 3).48 
This method has in fact been applied successfully to the construction of a variety of 
purine ring system bearing sensitive functional groups.27-33,38,49-53   
  
 
Scheme 3. Stille Coupling involves reaction of organostannane with an organohalide.     
R = C.    
 
1.4.4.1 Mechanism47 
The active compound Pd0(L)2 react with the organic electrophil, R-Cl. Step 1 is called 
oxidative addition were complex 1 is formed (Scheme 4). Palladium undergoes oxidation 
from 0 to II. A transmetallation occur in step 2. An organometallic compound will 
exchange the halide with an alkyl group. During this process complex 2 is formed, but it 
will undergo rapid transformation from trans to cis. This is called an isomerization 
reaction and lead to the formation of complex 3. In the third and last step, two 
alkylgroups (R-R’) will be reductive eliminated and form a new C-C bond. Palladium 
will simultaneously change oxidation number from II to 0 and the complex is now 
regenerated.    
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Scheme 447. Catalytic cycle. Cl is the outgoing group. L = catalyst ligand. R-R’ is the 
new compound formed in the reaction.     
                                                                                                                                                           
The major downfall for the Stille coupling reaction is the high toxicity of the trialkyl 
organostannane (ClSnBu3) formed in the reaction. Separation of the organotin from the 
desired product cannot be achieved because both are soluble in nonpolar organic solvent. 
In contrast to organotinchlorides and organotinbromides, the triaryltinfluorides are 
insoluble in organic solvents.54 When a solution of potassium fluoride (KF) in an organic 
solvent is added to the reaction mixture, the ClSnBu3 will be converted to the insoluble 
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FSnBu3 (Scheme 5). The tributyltin chloride can also be removed by dissolving the crude 
product in acetonitrile and extracting the tin chloride with hexane.33 Previously in our 
group organostannanes have been used to synthesize purine analogues.27-33,49-52 
Successful results have been achieved and therefore these conditions were applied in the 
Stille coupling reactions.    
 
ClSnBu3 + KF(aq) Æ  FSnBu3(s) + KCl(aq) 
Scheme 5. Converting organotin with potassium fluoride. 
 
1.4.5  Suzuki coupling  
The palladium-catalyzed cross-coupling reaction between organoboron compound and 
organic halides is called Suzuki coupling (Scheme 6). This is a powerful and general 
methodology for the formation of carbon-carbon bonds.38 The availability of the reagents 
and the mild reaction conditions contribute to the versatility of this reaction. Suzuki 
coupling has several advantages, such as being largely unaffected by the presence of 
water, tolerating a broad range of functional groups and proceeding generally regio- and 
stereoselectivity. Additionally, the inorganic by-product of the reaction is non-toxic and 
easily removed from the reaction mixture,  making the Suzuki coupling suitable not only 
for laboratories but also for industrial processes.48,55 Numerous purine derivates have 
been synthesized using this method.31,56-58          
 
 
Scheme 6. Suzuki couplings involve reaction of organoboron with an organohalide. 
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1.4.5.1 Mechanism55,59  
The first step is similar to Stille coupling, were the oxidative addition of the halide (R-Cl) 
form the organo-palladium species (1) (Scheme 7). Further reaction with a base gives the 
intermediate 2 and the halide is cleaved off (step 2). The organoboron (3) must be 
activated with base for the reaction to proceed. This is the difference between Suzuki 
mechanism and Stille coupling. The activated compound 4 is called “ate” complex. This 
negatively charged ate complex undergo a clean coupling reaction with compound 2 via 
transmetalation and the second organo-palladium species (5) in this reaction is formed 
(step 3). Reductive elimination gives the desired product (R-R’) and restores the original 
palladium catalyst. 
         
Scheme 7. Catalytic cycle. Cl is the outgoing group. L = catalyst ligand. R-R’ is the new 
compound formed in the reaction.     
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The boron reagent used in the Suzuki coupling is potassium triflouroborate and they were 
previously synthesized in our group. They are easily prepared from organoboronic acids 
by treatment with an aqueous solution of KHF2 (Scheme 8).60       
 
 
Scheme 8. Synthesis of potassium furan-2-yltrifluoroborat 
 
Potassium furan-2-yltrifluoroborat is stable in air, environmentally friendly and works 
very well in Suzuki coupling. The byproduct from this reaction is converted to harmless 
inorganic salts that are readily separable from the desired product.60 Suzuki coupling was 
performed on the compounds that had been subjected to Stille coupling. The purpose was 
to see which coupling works best in order of yield, reaction time and environmental and 
health issues.  
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1.4.6 Acetylation of amine 
Some of the coupling products were subjected to acetylation of amine in the purine 2-
position (Scheme 9). Acetic anhydride reacts with amine to form amide. The acetylation 
can be performed in organic solvent in the presence of a base. 41 Herein triethylamine has 
been used,32,61 but other bases like pyridine is also common.32,62 In these reactions the 
monoacetylated product is formed as a major product. Only acetic anhydride is used 
without base to shift the ratio to produce diacetylated compound in major amount.  .32,63        
 
 
 
 
Scheme 9. Acetylation of amine on purine 2-position, R = benzyl derivate with flour or 
chloride; (a) Monoacetylation; (b) Diacetylation.    
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2. SYNTHESIS OF MOLECULES 
 
Compounds 27a, 28a, 29a, 30a, 30b, 31a and 31b were the target molecules. This section 
discusses in detail how they were synthesized.   
 
• N-alkylation 
- 2,6-Dichloro-9-(2-fluorobenzyl)-9H-purine (23a) and 2,6-dichloro-7-(2-
fluorobenzyl)-7H-purine (23b)  
- 6-Chloro-9-(4-chlorobenzyl)-9H-purin-2-amine (25a) and 6-chloro-7-(4-
chlorobenzyl)-7H-purin-2-amine (25b)  
- 6-chloro-9-(2-fluorobenzyl)-9H-purin-2-amine (26a) and 6-chloro-7-(2-
fluorobenzyl)-7H-purin-2-amine (26b)  
 
• Stille vs. Suzuki coupling 
- 2-Chloro-9-(2-fluorobenzyl)-6-(furan-2-yl)-9H-purine (27a)  
- 9-(4-Chlorobenzyl)-6-(furan-2-yl)-9H-purin-2-amine (28a)  
- 9-(4-Fluorobenzyl)-6-(furan-2-yl)-9H-purin-2-amine (29a)  
 
• Acetylation of amine 
-  N-(9-(4-chlorobenzyl)-6-(furan-2-yl)-9Hpurin-2-yl)acetamide (30a) and N-
acetyl-N-(9-(4-chlorobenzyl)-6-(furan-2-yl)-9H-purin-2-yl)acetamide (30b)  
-  N-(9-(2-fluorobenzyl)-6-(furan-2-yl)-9H-purin-2-yl)acetamide (31a)  and N-
acetyl-N-(9-(2-fluorobenzyl)-6-(furan-2-yl)-9H-purin-2-yl)acetamide (31b)  
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2.1  N-alkylation 
Six different N-alkylated compounds were made. 23a, 25a and 26a served as starting 
material. These were synthesized because N-9 alkylated compounds have been reported 
as adenosine receptor antagonist,20 while N-7 alkylated compounds have not been 
reported as AR antagonist.   
 
2.1.1  Synthesis of 2,6-dichloro-9-(2-fluorobenzyl)-9H-purine (23a) and 2,6-dichloro-
7-(2-fluorobenzyl)-7H-purine (23b)  
 
2,6-Dichloro-9-(2-fluorobenzyl)-9H-purine (23a) was isolated in 61 % yield, together 
with 19 % of the N-7 benzylated isomer (23b). This was done by alkylation of 2,6-
dichloropurine27 (22a) with 2-fluorobenzyl chloride in DMF employing potassium 
carbonate as base at room temperature (Scheme 10).50    
 
N
N NH
N
Cl
Cl
(a) N
N N
N
Cl
Cl
+F
N
N N
N
Cl
Cl
F
22a 23a 23b
 
 
Scheme 10. Reagents and conditions: (a) 2-fluorobenzyl chloride, K2CO3, DMF, 20 
hours at r.t.   
 
The 1H NMR spectrum of the crude product showed the ratio distribution of isomers to 
be 5:1 (23a:23b), were the N-9 isomer was the dominant of the two. This regioisomeric 
ratio has been reported earlier for N-9/N-7 alkylation.42 When DMF is used as solvent the 
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N-9 isomer yield is normally higher, compared to when DMSO or DMA are used as 
solvents.49 The staring material was completely converted to products, judged by crude 
1H NMR and TLC. Since compound 23a was used in further reactions, this is indeed 
good condition. In order to purify both isomers from each another, two attempt of flash 
chromatography were required. Combination of ethyl acetate:hexane (1:1) was used as 
solvent. They were differentiated by HMQC and HMBC NMR experiment. Table 3 give 
some of the selected correlation from long range HMBC spectrum. 
 
Table 3. Selected correlation from long range HMBC spectrum for the N-9 isomer (23a). 
X = coupling between carbon and hydrogen.    
    
 
 
 C-4 C-5 C-8 
CH2 X  X 
H-8 X X  
 
Table 4. Selected correlation from long range HMBC spectrum for the N-7 isomer (23b). 
X = coupling between carbon and hydrogen.    
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 C-4 C-5 C-8 
CH2  X X 
H-8 X X  
 
 
Couplings from carbons C-4 and C-5 clearly verify each isomer. C-4 on N-9 compound 
(23a) couples to CH2 and H-8, whereas C-5 has the same correlation for the N-7 molecule 
(23b). Carbon 2 and 6 was differentiated by the number of heteroatom they were bound 
to. C-2 has two nitrogen and one chloride attached and this indicate a higher shift value 
compared to C-6.27,49 The other carbons were identified by direct correlation of hydrogen 
to the attached carbon (HMQC).   
 
2.1.2  Synthesis of 6-chloro-9-(4-chlorobenzyl)-9H-purin-2-amine (25a) and 6-
chloro-7-(4-chlorobenzyl)-7H-purin-2-amine (25b)  
 
2-Amino-6-chloropurine28,60 (24a) was N-alkylated with 4-chlorobenzyl chloride 
(Scheme 11). The reaction condition is the same as described above.  
 
 
 
Scheme 11. Reagents and conditions: (a) 4-chlorobenzyl chloride, K2CO3, DMF, 23 
hours at r.t.    
 
Optimization of the reaction condition for synthesis of compounds 25a and 25b is given 
in Table 5, entries 1-6.  
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Table 5. Optimization of the reaction condition for synthesis of compounds 25a and 25b.  
 
Entry Compound Ratio crude 
1H NMR 
(25a:25b) 
Amount 
(mg) 
Yield (%) Flash 
chromatography  
Solvent system 
1 
25a 
n.d 
268 18 EtOAc/Hexane 
(2:1)  25b - - 
2 
25a 
n.d 
437 30 EtOAc/Hexane 
(2:1) then (1:0) 25b - - 
3 
25a 
10:1 
930 63 EtOAc/Hexane 
(2:1) then (1:0) 25b - - 
4 
25a 
7:1 
190 13 DCM/MeOH 
(95:5) 
25b - - 
5 
25a 
n.d 
770 52 DCM/MeOH 
(98:2) then (94:6) 25b 202 15 
6 
25a 
4:1 
910 62 DCM/MeOH 
(98:2) & (90:10) 25b 200 14 
 
For entries 1 and 2 (Table 4) the minor N-7 isomer was not present in the crude 1H NMR 
or TLC. If N-7 alkylated products were formed, they were in quantity to low to be 
isolated. Because the compounds were slightly soluble in ethyl acetate/hexane, it resulted 
in poor yields. Compounds 25 have an amino group in the purine 2-position and they are 
highly polar compared to compounds 23. N-7 is more polar compared to N-9 and there is 
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a huge distance for the spots on TLC. N-7 isomer is only isolated when a combination of 
DCM/MeOH is used as solvent (entry 5 and 6, Table 4). Still it is possible to isolate a 
considerable amount of 25a with ethyl acetate/hexane, as entry 3 indicates. But this 
separation required a lot of solvent, because of the poor solubility of compounds 25a and 
25b. Entry 4 gave the lowest yield, and even though polar solvents were used N-7 isomer 
was not isolated. A small column was tested to see whether a quicker separation could be 
achieved, but this gave insufficient results. The ratio of N-9/N-7 in entry 5 is not 
determined, because of no data available.  
 
The isomers of compound 25 were also distinguished by HMQC and long range HMBC 
NMR experiments. The correlations are exactly the same as for compounds 23. This is 
illustrated in table 5 were C-4 and C-5 correlations prove the difference. Carbon 2 and 6 
was differentiated by the number of heteroatom they were bound to. C-2 has two nitrogen 
and one amino group attached and will therefore have higher shift value than C-6.32 
 
Table 6. Selected correlation from long range HMBC spectrum for the N-9 isomer (25a). 
X = coupling between carbon and hydrogen.  
 
 
 
 C-4 C-5 C-8 
CH2 X  X 
H-8 X X  
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Table 7. Selected correlation from long range HMBC spectrum for the N-7 isomer (25b). 
X = coupling between carbon and hydrogen.    
 
 
 C-4 C-5 C-8 
CH2  X X 
H-8 X X  
 
2.1.3  Synthesis of 6-chloro-9-(2-fluorobenzyl)-9H-purin-2-amine (26a) and 6-chloro-
7-(2-fluorobenzyl)-7H-purin-2-amine (26b)  
 
2-Amino-6-chloropurin28,64 (24a) was reacted with 2-fluorobenzyl chloride to give the 
two N-alkylated isomers 6-chloro-9-(2-fluorobenzyl)-9H-purin-2-amine (26a) and 6-
chloro-7-(2-fluorobenzyl)-7H-purin-2-amine (26b), respectively (Scheme 12). For 
reaction mechanism, see Scheme 2.   
 
 
 
Scheme 12. Reagents and conditions: (a) 2-fluorobenzyl chloride, K2CO3, DMF, 18 
hours at r.t.   
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The reaction condition was the same as for the synthesizing of compounds 23 and 25. 
Yields and amounts are given in Table 8.  
 
Table 8. Optimization of the reaction condition for synthesis of compounds 26a and 26b. 
Entry Compound Ratio crude 
1H NMR 
(25a:25b) 
Amount (mg) Yield (%) Flash chromatography  
Solvent system 
1 
26a 
11:1 
836 60 DCM/hexane/EtOAc
(1:1:2) then (0:0:1) 26b - - 
2 
26a 
5:1 
706 51 DCM/MeOH 
(95:5) then (90:10) 26b 64 5 
3 
26a 
n.d 
780 56 DCM/MeOH 
(95:5) then (90:10) 26b 30 2 
4 
26a 
10:1 
940 68 DCM/MeOH 
(95:5) then (90:10) 26b 80 6 
5 
26a 
n.d 
960 69 DCM/MeOH 
(95:5) then (90:10) 26b 100 7 
 
Here purine has an amino group in the 2-position as well. A mixture of 
DCM/hexane/EtOAc was not polar enough to isolate the N-7 isomer (entry 1, Table 6), 
even though it appeared on crude 1H NMR. But the yield of product 26a is good and the 
only disadvantage being the use of huge amount solvent during flash chromatography, 
again due to solubility issue. The time may also be considered as an issue, because the 
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efficiency is lowered. The best yields of compound 26a were achieved when a 
combination of DCM/MeOH was applied as solvent (entries 4 and 5, Table 6). 
Improvement in separation technique resulted in higher yield compared to entries 2 and 3. 
Flash chromatography was carried out twice for entry 2 in order to achieve best 
separation of the two isomers.  
 
Generally yields for the different isomers described here is within the range of what have 
been reported before.27,43,49,50 This is also the applicable for compounds 23 and 25. Even 
though compound 26a cannot be synthesized with complete selectivity, reaction 
condition can be optimized to increase the ratio of N-9 isomer compared to N-7. It is also 
worth noticing that N-9 isomer is always exclusively higher than N-7 alkylated product.         
The ratio of N-9/N-7 in crude 1H NMR for entries 3 and 5 is not determined, because of 
no data available.  
 
Characterisations of the two isomers (26) were done in the same manner as for products 
25. For long range HMBC correlation see Table 5. It is also possible to see the difference 
between the isomers by looking at where the shift values for certain carbons and 
hydrogen appear on NMR spectra. Table 9 gives a comparison of 1H and 13C NMR shift 
values for compounds 23a, 23b, 25a, 25b, 26a and 26b.   
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Table 9. Comparison of 1H and 13C NMR shift values for compounds 23a, 23b, 25a, 25b, 
26a and 26b.   
Compound Isomer 1H NMR 13C NMR 
  H-8 NH2 CH2 C-5 C-8 
23a N-9 8.79 - 41.4 130.4 148.3 
23b N-7 9.00 - 44.2 121.9 153.0 
25a N-9 8.21 6.93 45.4 123.3 143.1 
25b N-7 8.55 6.67 48.4 114.6 149.8 
26a N-9 8.14 6.92 40.1 123.4 143.2 
26b N-7 8.50 6.67 44.6 115.7 151.1 
 
 
The trend is now clearly seen from table 7. H-8 signals for N-9 isomers are shifted 
upfield to the corresponding H-8 signals for N-7 isomers. But the NH2 signals for N-9 
isomers (25 and 26) are shifted downfield to the corresponding NH2 signals for N-7 
isomers. The 13C NMR signals for CH2 and C-8 for the N-9 isomers are shifted upfield 
and shielded compared to the N-7 alkylated compounds. The most significant difference 
in ppm values is seen in C-5. They are deshielded relative to N-7 isomers. Similar 13C 
shift differences have been reported for hypoxanthine, adenine, 6-mercaptopurine 
regioisomeric derivatives and other purine compounds.39,65                
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2.2   Stille vs. Suzuki coupling 
Stille and Suzuki condition were performed on the same starting materials in order 
determine which coupling gave the best results. 
 
2.2.1   2-Choloropurine derivatives 
Compounds 18l and 18m (Table 2) have fluoride on the para- and meta-position on 
phenyl, respectively. They have been tested as selective antagonists for ARs. In order to 
see the effect of the fluoride position, it was decided to synthesize a molecule with orto 
position for the halogen with a EWD group on the purine 2-position (27a) (Figure 12).  
 
 
 
Figure 12.  Compound 27a is the target molecule.  
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2.2.1.1 Synthesis of 2-chloro-9-(2-fluorobenzyl)-6-(furan-2-yl)-9H-purine (27a)  
 
2,6-Dichloro-9-(2-fluorobenzyl)-9H-purine (23a) was coupled with the organostannane 
2-(tributylstannyl)furan in the presence of tetrakis[tri(2-furyl)phosphine]palladium(0) in 
DMF at 50 ºC (Scheme 13, a). 
 
 
 
Scheme 13. Reagents and condition: (a) Stille: 2-furylSnBu3, [(2-furyl)3P]4Pd, DMF, 18 
hours at 50 ºC; (b) Suzuki: (2-furylBF3)K, K2CO3, (Ph3P)2PdCl2, EtOH, 4 hours at 30-50 
ºC.  
 
Since compound 23a has two chlorines attached, there is a possibility for coupling in the 
purine 2-position as well.50 To receive a selective coupling in purine 6-posistion and the 
formation of the desired product 27a, mild reaction condition must be applied. Low 
reaction temperature and a more reactive catalyst like [(2-furyl)3P]4Pd is required.27,53 
Under these conditions the dichloropurine (23a) reacted with almost complete region 
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selectivity and gave the desired coupling product 27a in 50 % yield. 11 % of starting 
material was also recovered.  
The 6-position in purine moiety will readily undergo nucleophilic aromatic substitution 
reactions when treated with alcohols. It has been reported that calculations have also 
shown that purine 6-position is more reactive towards nucleophilic attack compared to 
purine 2-position.40 In the first attempt to synthesize 27a, 6-methoxypurine27 27b was 
observed. The ratio of the mixed compounds was 9:6 (27a:27b) and the products were 
confirmed by MS. Unfortunately they were inseparable by flash chromatography. During 
workup a saturated solution of KF in methanol was added in the crude mixture to convert 
the toxic co-product ClSnBu3 to the corresponding insoluble FSnBu3 (Scheme 5). In order 
to avoid alcohol and the formation of by-product 27b, KF in THF was used instead. This 
worked successfully and gave only the desired product 27a.                
 
The boron reagent potassium furan-2-yltrifluoroborat was coupled with 2,6-dichloro-9-
(2-fluorobenzyl)-9H-purine (23a) (Scheme 13, b). Bis(triphenylphosphine)palladium (II) 
chloride was used as catalyst. The chlorides help to stabilize the active zerovalent Pd (0) 
in solution.66 This catalyst has been utilized in a many couplings reactions previously 
performed in our group.27,29-33,49-52,67 In most cases DMF was the solvent. Ethanol was 
used as solvent because a test reaction had been done before and the coupling had 
worked. In additional it is a more environmental friendly solvent compared to DMF.  
 
The reaction was tracked on TLC while increasing the temperature. At 30 - 45 ºC no 
reaction took place, only when temperature was increased to 50 ºC product was seen on 
TLC. Reaction was stopped after four hours when no staring material was visible. During 
flash chromatography two fractions with different products were isolated. Both fractions 
had the same Rf value, they were differentiated by UV light. Initially only the product 
27a was expected to be isolated. In the first fraction 36 % of 6-ethoxypurine (27c) was 
isolated. Because of very short reaction time the staring material did not undergo 
nucleophilic aromatic substitution with ethanol. The second fraction contained a mixture 
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of the desired product 27a and compound 27d. The ratio was 1:7 (27a:27d) integrated 
from 1H NMR and they were confirmed by MS as well. It was not possible to separate 
them. The chloride on the desired compound 27a reacted with ethanol to give the side 
product 27d and very little product remained. The results indicate that there is a 
competition for the 6-position on purine. Nucleophilic aromatic substitution is faster 
compared to Suzuki coupling. But after coupling, purine 2-position is also prone for 
substitution by ethanol. This is due to the excess of ethanol, since it is used as a solvent 
there is no possibility of preventing the side reactions.    
 
 The structure for 2-chloro-6-ethoxy-9-(2-fluorobenzyl)-9H-purine (27c) could not be 
100 % confirmed based on the data available at this time. There is also a possibility that it 
is the other isomer with ethoxy on the 2-position and chloride on the 6-position. The 
carbon on purine which is bound to the ethoxy group has a shift value around 160 ppm, 
regardless of it is positioned on 2 or 6 carbon in the aromatic ring. In additional C-2 and 
C-6 will couple in a same manner to CH2-O hydrogen. As mentioned earlier it is well 
known that C-6 is much more reactive towards nucleophilic aromatic substitution 
compared to C-2. Even though interpretation of NMR spectra suggest isomer 27c, the 
data collected here is not enough to conclude which isomer it is. In order to determine the 
structure, compound 27c could have been crystallized and applied to x-ray 
crystallography.          
 
2.2.2   2-Aminopurine derivatives 
9-(4-Chlorobenzyl)-6-(furan-2-yl)-9H-purin-2-amine (28a) have previously been 
synthesized by Kiselgof et al as a selective antagonist for A2A AR.20 Compound 28a was 
decided to  synthesize in order explore the affinity for A1, A2B, A3 receptors and also to 
see the effect of number of chlorides on the phenyl ring. Compound 18o (Table 2) has 
two fluoride attached to the phenyl ring. In order to find out if the number of halogens 
affects the potency and selectivity for ARs, we chose to synthesize derivate 29a. In both 
cases there is a EWG on purines 2-position (Figure 13).  
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Figure 13.  Compound 28a and 29a are the target molecules.  
 
2.2.2.1   Synthesis of 9-(4-chlorobenzyl)-6-(furan-2-yl)-9H-purin-2-amine (28a)  
 
6-Chloro-9-(4-chlorobenzyl)-9H-purin-2-amine (25a) was coupled using different 
methods in order to give 9-(4-chlorobenzyl)-6-(furan-2-yl)-9H-purin-2-amine (28a) as 
product (Scheme 14).  
 
 
Scheme 14. Attempted conditions used for reaction optimization is listed in Table 10: 
Stille coupling entry 1-4 and Suzuki coupling entry 5-6.  
 
Table 10 gives an overview for the various methods used in Stille and Suzuki coupling to 
synthesize compound 28a.  
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Table 10. Attempted conditions used for reaction optimization for compound 28a. 
Entry R-(2-furyl) Catalyst Salt Solvent Temp 
(ºC) 
Time 
(h) 
Yield 
(%) 
1 
 
(Ph3P)2PdCl2 - DMF 90 18 61 
2 " [(2-furyl)3P]4Pd - " 50 18 - 
3 " [(2-furyl)3P]4Pd - " 90 18 27 
4 " PdCl2·dppf·CH2Cl2 
LiCl 
CsF 
" 90 18 31 
5 
OKF3B  
Pd(OAc)2(PPh3)2 K2CO3 EtOH 70-80 3 50 
6 " (Ph3P)2PdCl2 K2CO3 " 75 23 - 
  
Entry 1 (Table 10) gave 61 % yield when bis(triphenylphosphine)palladium (II) chloride 
was used as catalyst. But when the reaction was repeated for the second time using the 
same conditions, the product could not be isolated. Crude 1H NMR showed conversion of 
product. During flash chromatography a too small column was used and tin chloride 
adduct was mixed with product. Insufficient KF treatment (Scheme 5) caused movement 
of ClSnBu3 on the column. Product isolated in the mixed fraction was too little to flash 
again. Therefore entry 1 was run for the third time. This time Ph3PO formed by oxidation 
of the Ph3P-ligand interfered with 28a. This was proved by comparing reference 1H NMR 
spectra for Ph3PO. Both had same Rf value and could not be separated even though flash 
chromatography was done twice. In additional 20 % of starting material was also 
recovered.  
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To avoid Ph3PO interference with product, another ligand with different polarity was 
chosen. Tetrakis[tri(2-furyl)phosphine]palladium(0) was the catalyst when compound 
25a reacted with 2-(tributylstannyl)furan at 50 ºC in DMF (entry 2, Table 10). Low 
temperature gave little formation of product. A lot of staring material which was left 
unreacted, reacted further with methanol during tin chloride workup (Scheme 5). These 
reactions gave the by product 28b, confirmed by MS. Therefore pure product could not 
be isolated by flash chromatography. In order to gain better conversion of product 28a, 
the temperature was raised to 90 ºC (entry 3, Table 10). Since compound 25a has an 
amino group on purine 2-position it will not react with organostannane compared to 
staring material 23a. Entry 3 gave full conversion of starting material (25a) to product, 
judge by 1H NMR of crude mixture. The first attempt to isolate product gave a mixture 
with (2-furyl)3PO formed by oxidation of the (2-furyl)3P-ligand. The main product had a 
slightly lower Rf value compared to (2-furyl)3PO. Second flash chromatography run gave 
27 % of the desired product 28a. The yield was low due to multiple separations. 
 
Cesium fluoride is an activator for organotin reagents in Stille coupling reactions.68 It 
accelerates the transmetalation step in order to form a strong Sn-F bond, thus converting 
tin chloride adduct to the corresponding tin fluoride just like KF treatment (Scheme 
5).69,70 The presence of only CsF have previously been reported to convert majority of 
palladium catalyst to palladium black. To prevent decomposition lithium chloride was 
added with excess of CsF. These reactions have been reported to give high yields.71 In 
order to increase the yield for compound 28a, compound 25a was reacted with 2-
(tributylstannyl)furan employing [1,1’-Bis(diphenylphosphino)ferrocene] 
dichloropalladium (II)60 as catalyst, in the presence CsF and LiCl in DMF at 90 ºC (entry 
4, Table 10). But this gave only 31 % yield, even though crude TLC showed full 
conversion of 25a. A reason for this could be the fact that LiCl and CsF decomposes the 
starting material and this results in low yield. Another reason could be that the reaction 
was run over night with too high temperature (90 ºC).  
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Pd(OAc)2(PPh3)272 catalysed the Suzuki coupling between compound 25a and potassium 
furan-2-yltrifluoroborat in ethanol (entry 5, Table 10). The reaction was tracked on TLC. 
After 1.5 hours with 70 ºC product was viewed. Temperature was increased to 80 ºC and 
after 3 hours the reaction was stopped when no staring material was visible on TLC. The 
resulting crude mixture was purified by dry flash chromatography on silica gel using 
ethanol and filtrated with a mixture of hexane/ethanol/cold water. The product 
precipitated when a combination of Ethyl acetate/hexane was added. A new and less time 
consuming technique was developed herein without the use of ordinary flash 
chromatography. This gave 50 % of the desired product 28a.     
  
To increase the yield compared to entry 5 (Table 10), entry 6 was run over night with a 
set temperature at 75 ºC. Three different compounds were present in the crude mixture, 
judged by 1H NMR. After flash chromatography a mixture of compound 25a, 28a and 
28b was isolated in a ratio of 2:5:3 respectively. They were confirmed by MS as well. 
Pure products could not be isolated due to insufficient conversion of starting material. 
Suzuki coupling had taken place rather quickly and when the catalyst decomposed, the 
remaining starting material reacted with ethanol and by product 28b was formed. 
Compound 28b was not observed in entry 5. It seems like longer reaction time trigger 
formation of by product and the temperature should have been 80 ºC instead, in order to 
increase coupling speed.  
 
2.2.2.2   Synthesis of 9-(4-fluorobenzyl)-6-(furan-2-yl)-9H-purin-2-amine (29a)  
 
Organostannane 2-(tributylstannyl)furan and the boron reagent potassium furan-2-
yltrifluoroborat were Stille- or Suzuki coupled with 6-chloro-9-(2-fluorobenzyl)-9H-
purin-2-amine (26a) employing different method in order to give compound 29a (Scheme 
15).  
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Scheme 15. Attempted conditions used for reaction optimization is listed in Table 11: 
Stille coupling entry 1-4 and Suzuki coupling entry 5-6.  
 
Table 11 gives a detailed overview of how the synthesis of 9-(4-fluorobenzyl)-6-(furan-2-
yl)-9H-purin-2-amine (29a) was done.      
 
Table 11. Attempted conditions used for reaction optimization for compound 29a.  
Entry R-(2-furyl) Catalyst Salt Solvent Temp 
(ºC) 
Time 
(h) 
Yield 
(%) 
1 
 
(Ph3P)2PdCl2 - DMF 90 18 - 
2 " [(2-furyl)3P]4Pd - " 90 18 - 
3 " PdCl2·dppf·CH2Cl2 - " 90 18 - 
4 " PdCl2·dppf·CH2Cl2 
LiCl 
CsF 
" 90 18 29 
5 
 
Pd(OAc)2(PPh3)2 K2CO3 EtOH 75-85 4 83 
6 " (Ph3P)2PdCl2 K2CO3 " 80 4 72 
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 Again oxidization of ligand to Ph3PO gave problems during flash chromatograpgy for 
compound 29a as well (entry 1, Table 11). Pure product could not be isolated with ethyl 
acetate/ hexane, although no starting material could be seen from 1H NMR of crude 
mixture. The catalyst was changed to [(2-furyl)3P]4Pd in order to give different Rf value 
for product and oxidized ligand (entry 2, Table 11). Crude NMR showed full conversion 
of starting material. But flash chromatography gave many challenges. A too small 
column was used, insufficient KF treatment (Scheme 5) resulted in movement of tin 
chloride adduct on the column and the product was not able to move on the column due 
to the use of less polar solvent system (ethyl acetate/ hexane). Only 20 mg of compound 
29a was isolated, but it was contaminated with tin chloride adduct. To get a better 
separation, entry 2 (Table 11) was run for the second time. And again crude 1H NMR 
showed full conversion of starting material. The reaction condition is very good in term 
of reactivity. Different solvent systems were tried on TLC. When a combination of 
DCM/EtOH was employed during flash chromatography it gave good separation and 450 
mg (73 %) of 29a was isolated. Unfortunately some tin chloride adduct was also present 
because KF treatment did not work well. Apart from that, no other contaminations were 
present. See Figure 14 for 1H NMR.                   
 
 
Figure 14. 1H NMR of isolated compound 29a contaminated with ClSnBu3 in 1.8-0.8 
ppm region. (Entry 2, Table 11).    
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Acetonitrile was added to the isolated compound in order to remove ClSnBu3.33 But 
compound 29a was insoluble. Therefore a saturated solution of KF in THF was added and 
a second flash chromatography was performed with chloroform/MeOH. But almost all 
product got stuck on the column and could not be isolated again.  
 
6-Chloro-9-(2-fluorobenzyl)-9H-purin-2-amine (26a) was coupled with 2-
(tributylstannyl)furan. [1,1’-Bis(diphenylphosphino)ferrocene]dichloropalladium (II) was 
the catalyst (entry 3, Table 11). Crude NMR proved that Stille coupling had taken place. 
But little product was isolated (< 20 mg) and it also contained oxidized ligand. The same 
condition was applied once more, but this time CsF and LiCl were added (entry 4, Table 
11). This gave only 29 % of product 29a. Similarly for compound 28a with same 
condition (entry 4, Table 10), this also resulted in low yield. This verifies that with the 
salts involved, the starting material decomposes. The temperature and reaction time 
should also be decreased. 
 
Suzuki conditions were also explored with 6-chloro-9-(2-fluorobenzyl)-9H-purin-2-
amine (26a). In the fifth entry (table 11) Pd(OAc)2(PPh3)2 was the catalyst. Palladium (II) 
acetate has previously been reported to be successful in Suzuki coupling of boron 
reagent.60 The reaction was followed by TLC. After 1 hour at 75 ºC product formed. 
Temperature was increased to 85 ºC after 3.5 hours and stopped in the 4th hour when no 
starting material (26a) was visible on TLC. Product precipitated in the solvent during 
reaction. Filtration with water/hexane/ethanol/methanol gave 83 % yield. The new 
method for purification does not require ordinary flash chromatography and is the highest 
yield obtained for coupling reaction compared to the other entries (Table 10 and 11).  
 
In order to see how (Ph3P)2PdCl2 works as catalyst for Suzuki coupling for compound 
26a, entry 6 (Table 11) was run. The temperature was set to 80 ºC, based on reaction 
from entry 5 (Table 11). After 4 hours full conversion of starting material was achieved. 
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Flash chromatography with DCM/MeOH and crystallization with DCM/chloroform gave 
72 % yield. This is also a very good yield, indeed. No other by product was formed with 
the use of ethanol as solvent. This confirms that short and effective reaction gives only 
the desired product with 2-aminopurine derivatives (Scheme 14 and 15). For general 
reaction mechanism for Suzuki coupling, see Scheme 7.  
 
 2.3  Acetylation of amine 
Compound 18q and 18s, with mono- and diacetylated amine have been tested as selective 
antagonist for the ARs (Table 2, Figure 16). This is a new line of derivatives compound 
18, developed in our group. In order to see the quantitative and qualitative effect of 
halogen on the aromatic ring and the significance of mono- and diacetamide on purine 2-
position, 9-(4-chlorobenzyl)-6-(furan-2-yl)-9H-purin-2-amine (28a) and 9-(4-
fluorobenzyl)-6-(furan-2-yl)-9H-purin-2-amine (29a) were further subjected acetylation. 
Target molecules are presented in Figure 16.  
 
 
 
Figure 16.  Compounds 10a, 10b, 11a and 11b are the target molecules.  
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2.3.1 Synthesis of N-(9-(4-chlorobenzyl)-6-(furan-2-yl)-9Hpurin-2-yl)acetamide (30a) 
and N-acetyl-N-(9-(4-chlorobenzyl)-6-(furan-2-yl)-9H-purin-2-yl)acetamide (30b)  
 
9-(4-Chlorobenzyl)-6-(furan-2-yl)-9H-purin-2-amine (28a) was refluxed for 24 hours 
with acetic anhydride and triethylamine in toluene (Scheme 17, a). For reaction 
mechanism see Scheme 9.   
 
 
 
Scheme 17. Reagents and condition: (a) Ac2O, Et3N, Toluene, 24 hours of reflux; (b) 
Ac2O, Toluene, 48 hours of reflux.    
 
This gave the monoacetylated compound 30a in 53 % yield and diacetylated (30b) in 9 % 
yield. Compound 30b was only formed in minor amount when base was employed 
(Scheme 9).32,61 When base was not added (Scheme 17, b)32,62 N-acetyl-N-(9-(4-
chlorobenzyl)-6-(furan-2-yl)-9H-purin-2-yl)acetamide (30b) was formed in 66 % yield 
after 48 hour reflux. Less than 7 % of 30a was also formed, but it was mixed with a small 
amount of 30b. It has been proved herein that the selectivity is reversed and it is possible 
to control the quantity when base is added or removed. The compounds were separated 
by flash chromatography using ethyl acetate/ hexane.        
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2.3.2  N-(9-(2-fluorobenzyl)-6-(furan-2-yl)-9H-purin-2-yl) acetamide (31a) and N-
acetyl-N-(9-(2-fluorobenzyl)-6-(furan-2-yl)-9H-purin-2-yl) acetamide (31b)  
 
9-(4-Fluorobenzyl)-6-(furan-2-yl)-9H-purin-2-amine (29a) was reacted with the 
conditions described in Scheme 18 to give N-(9-(2-fluorobenzyl)-6-(furan-2-yl)-9H-
purin-2-yl)acetamide (31a) and N-acetyl-N-(9-(2-fluorobenzyl)-6-(furan-2-yl)-9H-purin-
2-yl)acetamide (31b).   
 
 
 
 
Scheme 18. Attempted conditions used for reaction optimization is listed in Table 12.  
Table 12. Attempted conditions used for reaction optimization for compounds 31a and 
31b. 
Entry 31a (%) 31b (%) Reagent Base Solvent Time (h) 
1 63 - Ac2O Et3N Toluene 24 
2 4 - ″ Et3N ″ 24 
3 59 4 ″ - ″ 48 
4 21 32 ″ - ″ 24 
 
58 
 
 
 
Entry 132,61 (Table 12) gave 63 % of compound 31a, when refluxed for 24 hours. Very 
minor amount of product 31b was isolated, but it was mixed with the monoacetylated 
compound (31a). It was only 10 mg. In order to synthesize more of compound 31b, the 
reaction was repeated (entry 2, Table 12). But this gave only 4 % of 31a, due to poor 
crystallization during work up. The base was removed (entry 3, Table 12)32,62,63 in order 
to achieve better selectivity of diacetylated compound like the one in Scheme 17, b. 
Surprisingly the selectivity was reversed and the monoacetylated was formed in major 
amount. In order to explore the effect of reaction time, entry 4 (Table 12) was run only 
for 24 hours. This shifted the ratio and the diacetylated compound (31b) was isolated in 
major amount by flash chromatography.           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
59 
 
 
 
3. CONCLUSION 
 
All the seven target molecules (27a, 28a, 29a, 30a, 30b, 31a and 31b) were successfully 
synthesized (Figure 17). They have been sent for biological testing for the various 
adenosine receptors, in order to see if they can be utilized as potential drugs in the future. 
The screening is carried out in the group of Professor Christa Müller at the University of 
Bonn.   
 
Figure 17. Target compounds presented with yields. 
For compound 23a with chloride on the 2-position Stille coupling worked better. By 
doing some optimization for the Suzuki coupling it is still possible to achieve pure 
product (27a). In this case the solvent must be non-nucleophilic to prevent side reaction 
with chlorides on the purine moiety. The temperature should be at 50 ºC and the other 
reagents can be kept as they were.  
Ethanol as solvent can be employed in Suzuki coupling for 2-aminopurines when the 
reaction time is short, but over night reactions produce by product and different solvent 
should be applied. Suzuki coupling works better for compound 25a, compared to Stille 
coupling. Suzuki coupling has been proved to be more efficient. Compared to Stille 
reactions, it has been additionally confirmed herein that Suzuki coupling gives highest 
yields, less time consuming reactions, less unhealthy, much easier purification, produce 
no toxic by products and most environmental friendly.  
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4. EXPERIMENTAL 
 
The 1H NMR spectra were recorded at 200 MHz a Bruker DPX 200 instrument or at 300 
MHz with a Bruker DPX 300 instrument. The 13C NMR spectra* were recorded at 75 or 
50 MHz using the above mentioned instruments. Peak assignment in 1H NMR and 13C 
NMR was based on information obtained from HMQC and HMBC spectroscopy. Mass 
spectra were recorded on a VG Prospec sector instrument from Fission Instrument at 70 
eV ionizing voltage and are presented as m/z (% rel. int.). Melting points were 
determined with a Büchi melting point B-545 apparatus and are uncorrected. Flash 
chromatography was done manually with silica gel from Merck (60, 40-63 µm).         
 
DMF and THF were taken dry from MBRAUN Solvent Purification System (SPS). 
Ethylacetate, hexane, dichloromethane, acetic anhydride, triethylamine and toluene were 
purified by distillation. Compound AN18a and potassium furan-2-yltrifluoroborat were 
previously synthesized in the group. All other reagents were commercially available and 
used as received. Elemental analyses were performed by Lianne Hill, School of 
Chemistry, University of Birmingham, England. 
 
 
 
 
 
 
 
                                                            
* In all 13C NMR spectra (except for compound 27a) there is a peak present at ca 79 ppm. This is due to 
noise from the NMR instrument.  
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2,6-dichloro-9-(2-fluorobenzyl)-9H-purine (23a) and 2,6-dichloro-7-(2-
fluorobenzyl)-7H-purine (23b)  
 
A mixture of 2,6-dichloropurine (22a) (944 mg, 5.00 mmol) and K2CO3 (2.07 g, 15.0 
mmol) in dry DMF (20 mL) was stirred at r.t. under N2 for 30 min., before 2-fluorobenzyl 
chloride (1.1 mL, 9.0 mmol) was added. The resulting mixture was stirred under r.t for 18 
h, filtered and evaporated in vacuo. The products were purified by flash chromatography 
on silica gel using ethyl acetate/hexane (1:1) followed by ethyl acetate. This gave 900 mg 
(61 %) of 2,6-dichloro-9-(2-fluorobenzyl)-9H-purine (23a) as a colourless powder and 
280 mg (19 %) of 2,6-dichloro-7-(2-fluorobenzyl)-7H-purine (23b) as a colourless 
powder.  
 
2,6-Dichloro-9-(2-fluorobenzyl)-9H-purine (23a) 
1H NMR (DMSO-d6, 300 MHz): δ 8.79 (s, 1H, H-8), 7.44-7.16 (m, 4H in Ar), 5.57 (s, 
2H, CH2). 
 
13C NMR (DMSO-d6, 75 MHz): δ 159.9 (d, JCF = 246 Hz, CF in Ar), 153.3 (C-4), 151.0 
(C-6), 149.7 (C-2), 148.3 (C-8), 130.5 (d, JCF = 8.2 Hz, CH in Ar), 130.4 (C-5), 130.1 (d, 
JCF = 3.8 Hz, CH in Ar), 124.7 (d, JCF = 3.5 Hz, CH in Ar), 122.3 (d, JCF = 14.5 Hz, C in 
Ar), 115.5 (d, JCF  = 20.8 Hz, CH in Ar), 41.4 (CH2). 
MS EI m/z (rel. %): 300/298/296 (5/27/40, M+), 109 (100), 83 (23).  
HR-MS Found 296.0029, calcd. for C12H7Cl2FN4 296.0032. 
M.p.  172 ºC 
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Spectrum 1. 1H of 2,6-dichloro-9-(2-fluorobenzyl)-9H-purine (23a). 
 
Spectrum 2. 13C of 2,6-dichloro-9-(2-fluorobenzyl)-9H-purine (23a). 
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Spectrum 3. HMQC of 2,6-dichloro-9-(2-fluorobenzyl)-9H-purine (23a). 
 
Spectrum 4. HMBC of 2,6-dichloro-9-(2-fluorobenzyl)-9H-purine (23a). 
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2,6-Dichloro-7-(2-fluorobenzyl)-7H-purine (23b) 
1H NMR (DMSO-d6, 300 MHz): δ 9.00 (s, 1H, H-8), 7.44-7.00 (m, 4H in Ar), 5.81 (s, 
2H, CH2). 
 
13C NMR (DMSO-d6, 75 MHz): δ 163.3 (C-4), 159.3 (d, JCF = 246 Hz, CF in Ar), 153.1 
(C-8), 151.2 (C-2), 143.1 (C-6), 130.2 (d, JCF = 8.3 Hz, CH in Ar), 128.5 (d, JCF = 3.5 Hz, 
CH in Ar), 124.9 (d, JCF = 3.5 Hz, CH in Ar), 123.4 (d, JCF = 13.9 Hz, C in Ar), 121.9 (C-
5), 115.4 (d, JCF  = 20.7 Hz, CH in Ar), 44.2 (CH2).  
MS EI m/z (rel. %): 300/298/296 (3/19/28, M+), 109 (100), 83 (15).  
HR-MS Found 296.0034, calcd. for C12H7Cl2FN4 296.0032. 
 M.p.  191 ºC 
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Spectrum 5. 1H of 2,6-dichloro-7-(2-fluorobenzyl)-7H-purine (23b). 
 
Spectrum 6. 13C of 2,6-dichloro-7-(2-fluorobenzyl)-7H-purine (23b). 
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Spectrum 7. HMQC of 2,6-dichloro-7-(2-fluorobenzyl)-7H-purine (23b). 
 
Spectrum 8. HMBC of 2,6-dichloro-7-(2-fluorobenzyl)-7H-purine (23b). 
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Synthesis of 6-chloro-9-(4-chlorobenzyl)-9H-purin-2-amine (25a) and 6-chloro-7-(4-
chlorobenzyl)-7H-purin-2-amine (25b)  
 
 
 
A mixture of 2-amino-6-chloropurine (24a) (846 mg, 5.00 mmol) and K2CO3 (2.06 g, 
15.0 mmol) in DMF (20 mL) was stirred at r.t. under N2 for 1 h. A solution of 4-
chlorobenzyl chloride (1.6 g, 0.01 mmol) in DMF (4 mL) was added and the resulting 
mixture was stirred at r.t for 23 h. The mixture was filtrated and evaporated in vacuo. The 
products were purified by flash chromatography on silica gel using different solvent 
systems (Table 13). This gave 6-chloro-9-(4-chlorobenzyl)-9H-purin-2-amine (25a) as a 
colourless fluffy powder and 6-chloro-7-(4-chlorobenzyl)-7H-purin-2-amine (25b) as a 
yellow powder. Amounts and yields are given in Table 13.  
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Table 13. Optimization of reaction conditions. 
Entry Compound Amount 
(mg) 
Yield 
(%) 
Flash 
chromatography 
Solvent system 
1 
25a 268 18 EtOAc/Hexane 
(2:1) 25b - - 
2 
25a 437 30 EtOAc/Hexane 
(2:1) then (1:0) 25b - - 
3 
25a 930 63 EtOAc/Hexane 
(2:1) then (1:0) 25b - - 
4 
25a 190 13 DCM/MeOH  
(95:5) 25b - - 
5 
25a 770 52 DCM/MeOH 
(98:2) then (94:6) 25b 202 15 
6 
25a 910 62 DCM/MeOH 
(98:2) then (90:10) 25b 200 14 
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6-Chloro-9-(4-chlorobenzyl)-9H-purin-2-amine (25a) 
1H NMR (DMSO-d6, 300 MHz): δ 8.21 (s, 1H, H-8), 7.40 (d, J = 7.3 Hz, 2H in Ar), 7.28 
(d, J = 7.3 Hz, 2H in Ar), 6.93 (br s, 2H, NH2), 5.28 (s, 2H, CH2). 
13C NMR (DMSO-d6, 75 MHz): δ 159.9 (C-6), 154.0 (C-4), 149.5 (C-2), 143.1 (C-8), 
135.6 (C in Ar), 132.4 (C-4 in Ar), 129.1 (CH in Ar), 128.7 (CH in Ar), 123.3 (C-5), 45.4 
(CH2).  
MS EI m/z (rel. %): 297/295/293 (5/33/51, M+), 127/125 (33/100), 89 (11). 
HR-MS Found 293.0235, calcd. for C12H9Cl2N5 293.0235. 
M.p.  212 ºC 
 
 
 
 
70 
 
 
 
 
Spectrum 9. 1H of 6-Chloro-9-(4-chlorobenzyl)-9H-purin-2-amine (25a) 
 
Spectrum 10. 13C of 6-Chloro-9-(4-chlorobenzyl)-9H-purin-2-amine (25a). 
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Spectrum 11. HMQC of 6-Chloro-9-(4-chlorobenzyl)-9H-purin-2-amine (25a). 
 
Spectrum 12. HMBC of 6-Chloro-9-(4-chlorobenzyl)-9H-purin-2-amine (25a). 
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6-Chloro-7-(4-chlorobenzyl)-7H-purin-2-amine (25b) 
1H NMR (DMSO-d6, 300 MHz): δ 8.55 (s, 1H, H-8), 7.41 (d, J = 9.0 Hz, 2H in Ar), 7.16 
(d, J = 9.0 Hz, 2H in Ar), 6.67 (br s, 2H, NH2), 5.55 (s, 2H, CH2). 
 
13C NMR (DMSO-d6, 75 MHz): δ 164.3 (C-2), 160.0 (C-6), 149.8 (C-8), 142.2 (C-4), 
136.1 (C in Ar), 132.2 (C-4 in Ar), 128.6 (CH in Ar), 128.2 (CH in Ar), 114.6 (C-5), 48.4 
(CH2). 
MS EI m/z (rel. %): 297/295/293 (4/25/38, M+), 127/125 (33/100), 89 (11). 
HR-MS Found 293.0234, calcd. for C12H9Cl2N5 293.0235.  
M.p.  222 ºC 
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Spectrum 13. 1H of 6-chloro-7-(4-chlorobenzyl)-7H-purin-2-amine (25b).  
 
Spectrum 14. 13C of 6-chloro-7-(4-chlorobenzyl)-7H-purin-2-amine (25b). 
74 
 
 
 
 
Spectrum 15. HMQC of 6-chloro-7-(4-chlorobenzyl)-7H-purin-2-amine (25b).   
 
Spectrum 16. HMBC of 6-chloro-7-(4-chlorobenzyl)-7H-purin-2-amine (25b).  
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Synthesis of 6-chloro-9-(2-fluorobenzyl)-9H-purin-2-amine (26a)  and 6-chloro-7-(2-
fluorobenzyl)-7H-purin-2-amine (26b)  
 
 
 
A mixture of 2-amino-6-chloropurin (24a) (845 mg, 5.00 mmol) and K2CO3 (2.07 g, 15.0 
mmol) in dry DMF (20 mL) was stirred at r.t. under N2 for 30 min., before 2-fluorobenzyl 
chloride (1.20 mL, 10.0 mmol) was added. The resulting mixture was stirred under r.t for 
18 h, filtered and evaporated in vacuo. The products were purified by flash 
chromatography on silica gel using different solvent systems (Table 14). This gave 6-
chloro-9-(2-fluorobenzyl)-9H-purin-2-amine (26a) as a yellow fluffy powder and of 6-
chloro-7-(2-fluorobenzyl)-7H-purin-2-amine (26b) as a colourless powder. Amounts and 
yields are given in Table 14. 
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Table 14. Optimization of reaction conditions. 
Entry Compound Amount 
(mg) 
Yield 
(%) 
Flash chromatography 
Solvent system 
1 
26a 836 60 DCM/hexane/EtOAc 
(1:1:2) then (0:0:1) 26b - - 
2 
26a 706 51 DCM/MeOH 
(95:5) then (90:10) 26b 64 5 
3 
26a 780 56 DCM/MeOH 
(95:5) then (90:10) 26b 30 2 
4 
26a 940 68 DCM/MeOH 
(95:5) then (90:10) 26b 80 6 
5 
26a 960 69 DCM/MeOH 
(95:5) then (90:10) 26b 100 7 
 
 
6-Chloro-9-(2-fluorobenzyl)-9H-purin-2-amine (26a) 
1H NMR (DMSO-d6, 300 MHz): δ 8.14 (s, 1H, H-8), 7.40-7.33 (m, 1H, H-3 in Ar), 7.26-
7.07 (m, 3H, H-2, H-4 and H-5 in Ar), 6.92 (br s, 2H, NH2), 5.34 (s, 2H, CH2).  
 
13C NMR (DMSO-d6, 75 MHz): δ 159.9 (C-2), 159.7 (d, JCF = 245 Hz, CF in Ar), 154.1 
(C-4), 149.5 (C-6), 143.2 (C-8), 130.1 (d, JCF = 8.3 Hz, CH in Ar), 129.3 (d, JCF = 3.8 Hz, 
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CH in Ar), 124.8 (d, JCF = 3.5 Hz, CH in Ar), 123.4 (C-5), 123.2 (d, JCF = 14.5 Hz, C in 
Ar), 115.5 (d, JCF  = 20.7 Hz, CH in Ar), 40.1 (CH2).  
MS EI m/z (rel. %): 279/277 (24/70, M +), 276 (6), 109 (100), 83 (11). 
HR-MS Found 277.0532, calcd. for C12H9ClFN5 277.0531. 
M.p.  190 ºC 
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Spectrum 17. 1H of 6-Chloro-9-(2-fluorobenzyl)-9H-purin-2-amine (26a). 
 
Spectrum 18. 13C of 6-Chloro-9-(2-fluorobenzyl)-9H-purin-2-amine (26a). 
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Spectrum 19. HMQC of 6-Chloro-9-(2-fluorobenzyl)-9H-purin-2-amine (26a). 
 
Spectrum 20. HMBC of 6-Chloro-9-(2-fluorobenzyl)-9H-purin-2-amine (26a). 
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6-Chloro-7-(2-fluorobenzyl)-7H-purin-2-amine (26b) 
1H NMR (DMSO-d6, 300 MHz): δ 8.50 (s, 1H, H-8), 7.41-7.34 (m, 1H, CH in Ar), 7.28-
7.22 (m, 1H, CH in Ar), 7.18-7.12 (m, 1H, CH in Ar), 6.90-6.85 (m, 1H, CH in Ar), 6.67 
(br s, 2H, NH2), 5.63 (s, 2H, CH2).  
 
13C NMR (DMSO-d6, 75 MHz): δ 165.2 (C-2), 160.9 (C-6), 160.2 (d, JCF = 245 Hz, CF 
in Ar), 151.1 (C-8), 143.2 (C-4), 130.8 (d, JCF = 8.2 Hz, CH in Ar), 129.0 (d, JCF = 3.8 
Hz, CH in Ar), 125.8 (d, JCF = 3.5 Hz, CH in Ar), 125.1 (d, JCF = 14.0 Hz, C in Ar), 
116.3 (d, JCF  = 20.7 Hz, CH in Ar), 115.7 (C-5), 44.6 (CH2).    
MS EI m/z (rel. %): 279/279 (18/56, M +), 109 (100), 83 (10).  
HR-MS Found 277.0532, calcd. for C12H9ClFN5 277.0531.  
M.p.  266 ºC 
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Spectrum 21. 1H of 6-Chloro-7-(2-fluorobenzyl)-7H-purin-2-amine (26b) 
 
Spectrum 22. 13C of 6-Chloro-7-(2-fluorobenzyl)-7H-purin-2-amine (26b). 
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Spectrum 23. HMQC of 6-Chloro-7-(2-fluorobenzyl)-7H-purin-2-amine (26b) 
 
Spectrum 24. HMBC of 6-Chloro-7-(2-fluorobenzyl)-7H-purin-2-amine (26b). 
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Synthesis of 2-chloro-9-(2-fluorobenzyl)-6-(furan-2-yl)-9H-purine (27a)  
 
N
N N
N
Cl
F
O
27a
 
 
Method 1 
 A mixture of tris(dibenzylideneacetone)dipalladium chloroform adduct (16 mg, 0.02 
mmol) and tri(2-furyl)phosphine (26 mg, 0.11 mmol) in DMF (4 mL) was stirred at r.t. 
under N2 for 15 min., before 2,6-dichloro-9-(2-fluorobenzyl)-9H-purine (23a/AN18a) 
(150 mg, 0.50 mmol) and 2-(tributylstannyl)furan (0.20 mL, 0.64 mmol) were added. The 
resulting mixture was stirred for 18 h at 50 ºC, cooled and evaporated in vacuo. KF (sat. 
sol. in THF, 10 mL) was added and the resulting mixture was stirred at r.t. for 18 h. The 
mixture was evaporated in vacuo. The product was purified by flash chromatography on 
silica gel using ethyl acetate/hexane (2:3) followed by pure ethyl acetate. This gave 82 
mg (50%) of 2-chloro-9-(2-fluorobenzyl)-6-(furan-2-yl)-9H-purine (27a) as a colourless 
powder.  
 
1H NMR (CDCl3, 300 MHz): δ 8.09 (s, 1H, H-8), 7.82 (dd, J = 3.5 Hz and 0.7 Hz, 1H, 
H-3 in furyl), 7.73 (dd, J = 1.7 Hz and 0.7 Hz, 1H, H-5 in furyl), 7.38 - 7.27 (m, 2H, H-3 
and H-4 in Ar), 7.13 - 7.04 (m, 2H, H-5 and H-6 in Ar), 6.63 (dd, J = 3.5 Hz and 1.7 Hz,  
1H, H-4 in furyl), 5.43 (s, 2H, CH2).        
13C NMR (CDCl3, 75 MHz): δ 160.7 (d, JCF = 247 Hz, CF in Ar), 154.5 (C-2), 153.5 (C-
4), 148.7 (C-2 in furyl), 147.3 (C-6), 146.7 (C-4 in furyl), 144.9 (C-8), 130.9 (d, JCF = 8.2 
Hz, CH in Ar), 130.7 (d, JCF = 3.2 Hz, CH in Ar), 126.9 (C-5) , 124.8 (d, JCF = 3.6 Hz, 
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CH in Ar), 121.8 (d, JCF = 14.5 Hz, C in Ar), 118.7 (C-3 in furyl), 115.8 (d, JCF  = 21.1 
Hz, CH in Ar), 112.8 (C-5 in furyl), 41.3 (CH2). 
MS EI m/z (rel. %): 330/328 (17/52 M+), 309 (8), 293 (4), 109 (100), 83 (15). 
HR-MS Found 328.0532, calcd. for C16H10ClFN4O 328.0527.   
Anal.: Found C, 58.53; H, 2.98; N, 16.59. C16H10ClFN4O requires C, 58.46; H, 3.07; N, 
17.04.  
M.p.  138 ºC 
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Spectrum 25. 1H of 2-chloro-9-(2-fluorobenzyl)-6-(furan-2-yl)-9H-purine (27a) 
 
Spectrum 26. 13C of 2-chloro-9-(2-fluorobenzyl)-6-(furan-2-yl)-9H-purine (27a). 
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Spectrum 27. HMQC of 2-chloro-9-(2-fluorobenzyl)-6-(furan-2-yl)-9H-purine (27a) 
 
Spectrum 28. HMBC of 2-chloro-9-(2-fluorobenzyl)-6-(furan-2-yl)-9H-purine (27a). 
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2-Chloro-6-ethoxy-9-(2-fluorobenzyl)-9H-purine (27c)  
 
 
 
2,6-Dichloro-7-(4-chlorobenzyl)-7H-purine (23a) (593 mg, 2.00 mmol), potassium furan-
2-yltrifluoroborat (0.45 g, 2.56 mmol), K2CO3 (0.83 g, 6.0 mmol) and 
bis(triphenylphosphine)palladium (II) chloride (43 mg, 0.06 mmol) were added in ethanol 
(200 mL). The resulting mixture was stirred under N2 for 2 h at 30 ºC, 30 min at 45 ºC 
and for 1.5 h at 50 ºC. The resulting crude mixture was purified by dry flash 
chromatography on silica gel using ethanol and filtrated with a mixture of ethanol/cold 
water. The mixture was evaporated in vacuo. The product was purified by flash 
chromatography on silica gel using ethyl acetate/hexane (2:4) followed by pure ethyl 
acetate. This gave 220 mg (36%) of 2-chloro-6-ethoxy-9-(2-fluorobenzyl)-9H-purine 
(27c) as a colourless powder.  
 
1H NMR (DMSO-d6, 300 MHz): δ 8.46 (s, 1H, H-8), 7.45-7.13 (m, 4H in Ar), 5.49 (s, 
2H, CH2), 4.57 (q, J = 7.07 Hz, 2H, CH2), 1.40 (t, J = 7.08 Hz, 3H, CH3).  
 
13C NMR (DMSO-d6, 75 MHz): δ 160.4 (C-6 or C-2), 159.8 (d, JCF = 246 Hz, CF in Ar), 
153.1 (C-4), 151.4 (C-2 or C-6), 144.4 (C-8), 130.3 (d, JCF = 8.2 Hz, CH in Ar), 129.8 (d, 
JCF = 3.7 Hz, CH in Ar), 124.7 (d, JCF = 3.6 Hz, CH in Ar), 122.8 (d, JCF = 14.5 Hz, C in 
Ar), 119.6 (C-5), 115.5 (d, JCF  = 20.7 Hz, CH in Ar), 63.7 (OCH2), 40.9 (CH2), 14.1 
(CH3).  
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MS EI m/z (rel. %): 308/306 (6/18, M+), 293/291 (5/15), 278/280 (11/4), 262/264 (6/2), 
227 (10), 109 (100), 83 (12).  
HR-MS Found 306.0682, calcd. for C14H12ClFN4O 306.0684.  
M.p.  110 ºC 
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Spectrum 29. 1H of 2-chloro-6-ethoxy-9-(2-fluorobenzyl)-9H-purine (27c) 
 
Spectrum 30. 13C of 2-chloro-6-ethoxy-9-(2-fluorobenzyl)-9H-purine (27c). 
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Spectrum 31. HMQC of 2-chloro-6-ethoxy-9-(2-fluorobenzyl)-9H-purine (27c) 
 
Spectrum 32. HMBC of 2-chloro-6-ethoxy-9-(2-fluorobenzyl)-9H-purine (27c). 
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Synthesis of 9-(4-chlorobenzyl)-6-(furan-2-yl)-9H-purin-2-amine (28a)  
 
 
 
 
 
Method 1 
A mixture of 6-chloro-9-(4-chlorobenzyl)-9H-purin-2-amine (25a) (155 mg, 0.53 mmol), 
bis(triphenylphosphine)palladium (II) chloride (18 mg, 0.03 mmol) and 2-
(tributylstannyl)furan (0.25 mL, 0.80 mmol) in DMF (2.6 mL) was stirred at 90 ºC under 
N2 for 18 h, cooled and evaporated in vacuo. KF (sat. sol. in MeOH, 2.6 mL) was added 
and the resulting mixture was stirred at r.t. for 18 h. The mixture was evaporated in 
vacuo. The product was purified by flash chromatography on silica gel using ethyl 
acetate/hexane (1:1). This gave 104 mg (61 %) of 9-(4-chlorobenzyl)-6-(furan-2-yl)-9H-
purin-2-amine (28a) as a yellow powder.  
 
Method 2 
A mixture of tris(dibenzylideneacetone)dipalladium chloroform adduct (38.5 mg, 0.04 
mmol) and tri(2-furyl)phosphine (63.3 mg, 0.27 mmol) in DMF (9.8 mL) was stirred at 
r.t. under N2 for 15 min., before 6-chloro-9-(4-chlorobenzyl)-9H-purin-2-amine (25a) 
(365 mg, 1.24 mmol) and 2-(tributylstannyl)furan (0.50 mL, 0.59 mmol) were added. The 
resulting mixture was stirred for 18 h at 90 ºC, cooled and evaporated in vacuo. KF (sat. 
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sol. in THF, 9.8 mL) was added and the resulting mixture was stirred at r.t. for 18 h. The 
mixture was evaporated in vacuo. The product was purified by flash chromatography on 
silica gel using ethyl acetate/hexane (1:1) followed by pure ethyl acetate. This gave 110 
mg (27 %) of 9-(4-chlorobenzyl)-6-(furan-2-yl)-9H-purin-2-amine (28a) as a yellow 
powder.  
 
Method 3 
A mixture of 6-chloro-9-(4-chlorobenzyl)-9H-purin-2-amine (25a) (588 mg, 2.00 mmol), 
[1,1’-Bis(diphenylphosphino)ferrocene]dichloropalladium (II) (82 mg, 0.1 mmol), 2-
(tributylstannyl)furan (0.81 mL, 2.56 mmol), LiCl (0.25 g, 6.0 mmol) and CsF (0.90 g, 
6.0 mmol) in DMF (25 mL) was stirred at 90 ºC under N2 18 h, cooled and evaporated in 
vacuo. The resulting crude mixture was dry flashed on silica gel using acetone. KF (sat. 
sol. in THF, 25 mL) was added and the resulting mixture was stirred at r.t. for 18 h. The 
mixture was evaporated in vacuo. The product was purified by flash chromatography on 
silica gel using DCM/methanol (98:2) followed by DCM/methanol (96:4). This gave 200 
mg (31 %) of 9-(4-chlorobenzyl)-6-(furan-2-yl)-9H-purin-2-amine (28a) as a yellow 
powder.  
 
Method 4 
6-Chloro-9-(4-chlorobenzyl)-9H-purin-2-amine (25a) (588 mg, 2.00 mmol), potassium 
furan-2-yltrifluoroborat (0.45 g, 2.56 mmol), K2CO3 (0.83 g, 6.0 mmol), palladium (II) 
acetat (14 mg, 0.06 mmol) and triphenylphosphine (115 mg, 0.44 mmol) were added in 
ethanol (200 mL). The resulting mixture was stirred under N2 for 1.5 h at 70 ºC and 1.5 h 
at 80 ºC.  The resulting crude mixture was purified by dry flash chromatography on silica 
gel using ethanol and filtrated with a mixture of hexane/ethanol/cold water. The mixture 
was evaporated in vacuo. Ethyl acetate and hexane were added and the product 
precipitated. This gave 375 mg (50 %) of 9-(4-chlorobenzyl)-6-(furan-2-yl)-9H-purin-2-
amine (28a) as a yellow powder.  
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 1H NMR (DMSO-d6, 300 MHz): δ 8.20 (s, 1H, H-8), 7.79 (dd, J = 1.7 Hz and 0.7 Hz, 
1H, H-5 in furyl), 7.72 (dd, J = 3.4 Hz and 0.7 Hz, 1H, H-3 in furyl), 7.40 (d, J = 8.6 Hz, 
2H in Ar), 7.28 (d, J = 8.6 Hz, 2H in Ar), 6.74 (dd, J = 3.4 Hz and 1.7 Hz, 1H, H-4 in 
furyl) , 6.59 (br s, 2H, NH2), 5.32 (s, 2H, CH2).  
 
13C NMR (DMSO-d6, 75 MHz): δ 160.4 (C-2), 153.7 (C-4), 149.4 (C-2 in furyl), 145.6 
(C-6), 145.4 (C-5 in furyl), 142.4 (C-8), 136.0 (C in Ar), 132.3 (C-4 in Ar), 128.7 (CH in 
Ar), 128.1 (CH in Ar), 121.6 (C-5), 116.4 (C-3 in furyl), 112.4 (C-4 in furyl), 45.0 (CH2). 
MS EI m/z (rel. %): 327/325 (33/100, M+), 324 (23), 214 (5), 200 (22), 127/125 (19/61), 
89 (8).  
HR-MS Found 325.0731, calcd. for C16H12ClN5O 325.0730. 
Anal.: Found C, 58.67; H, 3.59; N, 21.33. C16H12ClN5O requires C, 58.99; H, 3.71; N, 
21.50.  
M.p.  178 ºC 
 
Compound 28a is known in literature.20 
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Spectrum 33. 1H of 9-(4-chlorobenzyl)-6-(furan-2-yl)-9H-purin-2-amine (28a) 
 
Spectrum 34. 13C of 9-(4-chlorobenzyl)-6-(furan-2-yl)-9H-purin-2-amine (28a). 
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Spectrum 35. HMQC of 9-(4-chlorobenzyl)-6-(furan-2-yl)-9H-purin-2-amine (28a) 
 
Spectrum 36. HMBC of 9-(4-chlorobenzyl)-6-(furan-2-yl)-9H-purin-2-amine (28a). 
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Synthesis of 9-(4-fluorobenzyl)-6-(furan-2-yl)-9H-purin-2-amine (29a) 
 
 
Method 1 
A mixture of 6-chloro-9-(2-fluorobenzyl)-9H-purin-2-amine (26a) (554 mg, 2.00 mmol), 
[1,1’-Bis(diphenylphosphino)-ferrocene]dichloropalladium (II) (82 mg, 0.1 mmol), 2-
(tributylstannyl)furan (0.81 mL, 2.56 mmol), LiCl (0.25 g, 6.0 mmol) and CsF (0.90 g, 
6.0 mmol) in DMF (25 mL) was stirred at 90 ºC under N2 for 18 h, cooled and evaporated 
in vacuo. The resulting crude mixture was purified by dry flash chromatography on silica 
gel using acetone. KF (sat. sol. in THF, 25 mL) was added and the resulting mixture was 
stirred at r.t. for 18 h. The mixture was evaporated in vacuo. The product was purified by 
flash chromatography on silica gel using DCM/methanol (98:2). This gave 180 mg (29 
%) of 9-(4-fluorobenzyl)-6-(furan-2-yl)-9H-purin-2-amine (29a) as a colourless powder.  
 
Method 2 
6-Chloro-9-(2-fluorobenzyl)-9H-purin-2-amine (26a) (554 mg, 2.00 mmol), potassium 
furan-2-yltrifluoroborat (0.45 g, 2.56 mmol), K2CO3 (0.83 g, 6.0 mmol), palladium (II) 
acetat (14 mg, 0.06 mmol) and triphenylphosphine (115 mg, 0.44 mmol) were added in 
ethanol (67 mL). The resulting mixture was stirred under N2 for 3.5 h at 75 ºC and 30 
min. at 85 ºC.  Ethanol and water were added to the crude mixture and heated up to the 
boiling point. The solution was cooled in fridge over night. The mixture was filtrated 
with hot hexane. The remaining product in the filter paper was then filtrated with hot 
methanol. The product was evaporated in vacuo. This gave 510 mg (83 %) of 9-(4-
fluorobenzyl)-6-(furan-2-yl)-9H-purin-2-amine (29a) as a colourless powder. 
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Method 3 
A mixture of  6-chloro-9-(2-fluorobenzyl)-9H-purin-2-amine (26a) (554 mg, 2.00 mmol), 
potassium furan-2-yltrifluoroborat (0.45 g, 2.56 mmol), K2CO3 (0.83 g, 6.0 mmol), 
palladium (II) acetat (14 mg, 0.06 mmol) and triphenylphosphine (115 mg, 0.44 mmol) in 
ethanol (200 mL) was stirred under N2 for 4 h at 80 ºC. The mixture was filtered and 
evaporated in vacuo. The product was purified by flash chromatography on silica gel 
using DCM/methanol (97:3) and crystallized from DCM/chloroform. This gave 445 mg 
(72 %) of 9-(4-fluorobenzyl)-6-(furan-2-yl)-9H-purin-2-amine (29a) as a colourless 
powder. 
 
1H NMR (DMSO-d6, 300 MHz): δ 8.16 (s, 1H, H-8), 7.96 (dd, J = 1.8 Hz and 0.8 Hz, 
1H, H-5 in furyl), 7.73 (dd, J = 3.4 Hz and 0.8 Hz, 1H, H-3 in furyl), 7.42-7.04 (m, 4H, 
CH in Ar), 6.74 (dd, J = 3.4 Hz and 1.8 Hz, 1H, H-4 in furyl), 6.59 (br s, 2H, NH2), 5.37 
(s, 2H, CH2). 
 
13C NMR (DMSO-d6, 75 MHz): δ 160.3 (C-2), 159.7 (d, JCF = 245 Hz, CF in Ar), 153.7 
(C-4), 149.3 (C-2 in furyl), 145.6 (C-6), 145.4 (C-5 in furyl), 142.4 (C-8), 129.9 (d, JCF = 
8.2 Hz, CH in Ar), 129.2 (d, JCF = 3.8 Hz, CH in Ar), 124.7 (d, JCF = 3.5 Hz, CH in Ar), 
123.6 (d, JCF = 14.6 Hz, C in Ar), 121.4 (C-5), 116.3 (C-3 in furyl), 115.4 (d, JCF  = 20.7 
Hz, CH in Ar), 112.4 (C-4 in furyl), 39.7 (CH2).   
MS EI m/z (rel. %): 309 (100, M+), 290 (6), 200 (28), 109 (49), 83 (6).  
HR-MS Found 309.1029, calcd. for C16H12FN5O 309.1026.  
Anal.: Found C, 62.44; H, 4.08; N, 22.62. C16H12FN5O requires C, 62.13; H, 3.91; N, 
22.64. 
M.p.  192 ºC 
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Spectrum 37. 1H of 9-(4-fluorobenzyl)-6-(furan-2-yl)-9H-purin-2-amine (29a) 
 
Spectrum 38. 13C of 9-(4-fluorobenzyl)-6-(furan-2-yl)-9H-purin-2-amine (29a). 
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Spectrum 39. HMQC of 9-(4-fluorobenzyl)-6-(furan-2-yl)-9H-purin-2-amine (29a) 
 
Spectrum 40. HMBC of 9-(4-fluorobenzyl)-6-(furan-2-yl)-9H-purin-2-amine (29a). 
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Synthesis of N-(9-(4-chlorobenzyl)-6-(furan-2-yl)-9Hpurin-2-yl)acetamide (30a)  and 
N-acetyl-N-(9-(4-chlorobenzyl)-6-(furan-2-yl)-9H-purin-2-yl)acetamide (30b)  
 
 
 
 
Method 1 
Acetic anhydride (0.27 mL, 2.90 mmol) was added to a stirred suspension of 6-chloro-9-
(4-chlorobenzyl)-9H-purin-2-amine (28a) (101 mg, 0.33 mmol) and triethylamine (0.23 
mL, 1.70 mmol) in toluene (3.30 mL) and the resulting mixture was heated at reflux for 
24 h, cooled and evaporated in vacuo. The products were purified by flash 
chromatography on silica gel using ethyl acetate/hexane (2:1). This gave 64 mg (53 %) of  
N-(9-(4-chlorobenzyl)-6-(furan-2-yl)-9Hpurin-2-yl)acetamide (30a) as a pale yellow 
powder and 12 mg (9 %) of N-acetyl-N-(9-(4-chlorobenzyl)-6-(furan-2-yl)-9H-purin-2-
yl)acetamide (30b) as a colourless powder.  
 
Method 2 
A stirred suspension of 6-chloro-9-(4-chlorobenzyl)-9H-purin-2-amine (28a) (110 mg, 
0.36 mmol) in toluene (3 mL) was heated at reflux for 24 h. Acetic anhydride (0.34 mL, 
3.60 mmol) was added. After additional 24 h reflux, the solution was evaporated in 
vacuo. The product was purified by flash chromatography on silica gel using ethyl 
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acetate/hexane (2:1). This gave 98 mg (66 %) of N-acetyl-N-(9-(4-chlorobenzyl)-6-
(furan-2-yl)-9H-purin-2-yl)acetamide (30b) as a colourless powder.  
 
N-(9-(4-chlorobenzyl)-6-(furan-2-yl)-9Hpurin-2-yl)acetamide (30a) 
 
1H NMR (DMSO-d6, 300 MHz): δ 10.58 (br s, 1H, NH), 8.60 (s, 1H, H-8), 8.06 (dd, J = 
1.7 Hz and 0.7 Hz, 1H, H-5 in furyl), 7.82 (dd, J = 3.5 Hz and 0.7 Hz, 1H, H-3 in furyl), 
7.49 (d, J = 9.0 Hz, 2H in Ar), 7.41 (d, J = 9.0 Hz, 2H in Ar), 6.81 (dd, J = 3.5 Hz and 1.7 
Hz, 1H, H-4 in furyl), 5.43 (s, 2H, CH2), 2.24 (s, 3H, CH3).  
 
13C NMR (DMSO-d6, 75 MHz): δ 169.0 (CO), 152.7 (C-4), 152.5 (C-2), 148.7 (C-2 in 
furyl), 146.3 (C-5 in furyl), 145.4 (C-8), 145.1 (C-6), 135.4 (C in Ar), 132.6 (C-4 in Ar), 
129.8 (CH in Ar), 128.6 (CH in Ar), 124.5 (C-5), 117.5 (C-3 in furyl), 112.8 (C-4 in 
furyl), 45.6 (CH2), 24.5 (CH3).   
  MS EI m/z (rel. %): 369/367 (25/71, M+), 327/325 (34/100), 214 (6), 200 (21), 127/125 
(27/84), 89 (10).  
HR-MS Found 367.0829, calcd. for C18H14ClN5O2 367.0836.  
Anal.: Found C, 58.83; H, 3.86; N, 19.36. C18H14ClN5O2 requires C, 58.78; H, 3.84; N, 
19.04. 
M.p.  190 ºC 
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Spectrum 41. 1H of N-(9-(4-chlorobenzyl)-6-(furan-2-yl)-9Hpurin-2-yl)acetamide (30a). 
 
Spectrum 42. 13C of N-(9-(4-chlorobenzyl)-6-(furan-2-yl)-9Hpurin-2-yl)acetamide (30a). 
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Spectrum 43. HMQC of N-(9-(4-chlorobenzyl)-6-(furan-2-yl)-9Hpurin-2-yl)acetamide (30a). 
 
Spectrum 44. HMBC of N-(9-(4-chlorobenzyl)-6-(furan-2-yl)-9Hpurin-2-yl)acetamide (30a). 
104 
 
 
 
N-acetyl-N-(9-(4-chlorobenzyl)-6-(furan-2-yl)-9H-purin-2-yl)acetamide (30b) 
 
1H NMR (DMSO-d6, 300 MHz): δ 8.88 (s, 1H, C-8), 8.10 (dd, J = 1.7 Hz and 0.7 Hz, 
1H, H-5 in furyl), 7.93 (dd, J = 3.5 Hz and 0.7 Hz, 1H, H-3 in furyl), 7.42 (d, J = 9.0 Hz, 
2H in Ar), 7.38 (d, J = 9.0 Hz, 2H in Ar), 6.85 (dd, J = 3.5 Hz and 1.7 Hz, 1H, H-4 in 
furyl), 5.53 (s, 2H, CH2), 2.20 (s, 6H, 2 × CH3). 
 
13C NMR (DMSO-d6, 75 MHz): δ 171.9 (2 × CO), 153.1 (C-4), 152.4 (C-2), 148.0 (C-8), 
147.9 (C-2 in furyl), 147.0 (C-5 in furyl), 145.9 (C-6), 135.0 (C in Ar), 132.6 (C-4 in Ar), 
129.5 (CH in Ar), 128.6 (CH in Ar), 126.9 (C-5), 118.6 (C-3 in furyl), 113.1 (C-4 in 
furyl), 45.9 (CH2), 25.7 (2 × CH3). 
MS EI m/z (rel. %): 411/409 (4/14, M+), 369/367 (16/48), 354/352 (27/83), 327/325 
(17/53), 200 (11), 127/125 (30/100), 89 (10).  
HR-MS Found 409.0948, calcd. for C20H16ClN5O3 409.0942. 
Anal.: Found C, 58.40; H, 4.09; N, 17.32. C20H16ClN5O3 requires C, 58.61; H, 3.94; N, 
17.09. 
M.p.  199 ºC 
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Spectrum 45. 1H of N-acetyl-N-(9-(4-chlorobenzyl)-6-(furan-2-yl)-9H-purin-2-
yl)acetamide (30b). 
Spectrum 46. 13C of N-acetyl-N-(9-(4-chlorobenzyl)-6-(furan-2-yl)-9H-purin-2-
yl)acetamide (30b). 
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Spectrum 47. HMQC of N-acetyl-N-(9-(4-chlorobenzyl)-6-(furan-2-yl)-9H-purin-2-
yl)acetamide (30b).  
 
Spectrum 48. HMBC of N-acetyl-N-(9-(4-chlorobenzyl)-6-(furan-2-yl)-9H-purin-2-
yl)acetamide (30b) 
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Synthesis of N-(9-(2-fluorobenzyl)-6-(furan-2-yl)-9H-purin-2-yl)acetamide (31a) and 
N-acetyl-N-(9-(2-fluorobenzyl)-6-(furan-2-yl)-9H-purin-2-yl)acetamide (31b)  
 
 
 
 
Method 1 
Acetic anhydride (0.22 mL, 2.30 mmol) was added to a stirred suspension of 9-(4-
fluorobenzyl)-6-(furan-2-yl)-9H-purin-2-amine (29a) (81 mg, 0.26 mmol) and 
triethylamine (0.18 mL, 1.42 mmol) in toluene (2.60 mL) and the resulting mixture was 
heated at reflux for 24 h, cooled and evaporated in vacuo. The product was purified by 
flash chromatography on silica gel using ethyl acetate/hexane (2:1) followed by ethyl 
acetate. This gave 50 mg (63 %) of N-(9-(2-fluorobenzyl)-6-(furan-2-yl)-9H-purin-2-
yl)acetamide (31a) as a colourless powder.  
 
Method 2  
Acetic anhydride (0.46 mL, 4.90 mmol) was added to a stirred suspension of 9-(4-
fluorobenzyl)-6-(furan-2-yl)-9H-purin-2-amine (29a) (160 mg, 0.50 mmol) and 
triethylamine (0.34 mL, 2.40 mmol) in toluene (5 mL) and the resulting mixture was 
heated at reflux for 24 h, cooled and evaporated in vacuo. The product was purified by 
flash chromatography on silica gel using ethyl acetate/hexane (1:1) followed by ethyl 
acetate and crystallized from ethyl acetate/hexane. This gave 4.5 mg (3 %) of N-(9-(2-
fluorobenzyl)-6-(furan-2-yl)-9H-purin-2-yl)acetamide (31a) as a colourless powder.     
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Method 3 
A stirred suspension of  9-(4-fluorobenzyl)-6-(furan-2-yl)-9H-purin-2-amine (29a) (190 
mg, 0.60 mmol) in toluene (5 mL) was heated at reflux for 24 h. Acetic anhydride (0.57 
mL, 6.0 mmol) was added. After additional 24 h reflux, the solution was evaporated in 
vacuo. The products were purified by flash chromatography on silica gel using ethyl 
acetate/hexane (1:2) followed by ethyl acetate/hexane (2:3). This gave 110 mg (59 %) of 
N-(9-(2-fluorobenzyl)-6-(furan-2-yl)-9H-purin-2-yl)acetamide (31a) as a colourless 
powder and 10 mg (4 %) of  N-acetyl-N-(9-(2-fluorobenzyl)-6-(furan-2-yl)-9H-purin-2-
yl)acetamide (31b) as colourless crystals.   
 
Method 4 
Acetic anhydride (0.57 mL, 6.0 mmol) was added to a stirred suspension of 9-(4-
fluorobenzyl)-6-(furan-2-yl)-9H-purin-2-amine (29a) (190 mg, 0.60 mmol) in toluene (5 
mL). The mixture was heated at reflux for 24 h, cooled and evaporated in vacuo. The 
products were purified by flash chromatography on silica gel using DCM/ethanol (98:2).  
This gave 40 mg (21 %) of N-(9-(2-fluorobenzyl)-6-(furan-2-yl)-9H-purin-2-
yl)acetamide (31a) as a colourless powder and 80 mg (32 %) of  N-acetyl-N-(9-(2-
fluorobenzyl)-6-(furan-2-yl)-9H-purin-2-yl)acetamide (31b) as colourless crystals.   
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N-(9-(2-fluorobenzyl)-6-(furan-2-yl)-9H-purin-2-yl)acetamide (31a) 
 
1H NMR (DMSO-d6, 300 MHz): δ 10.53 (br s, 1H, NH), 8.52 (s, 1H, H-8), 8.04 (dd, J = 
1.7 Hz and 0.8 Hz, 1H, H-5 in furyl), 7.81 (dd, J = 3.5 Hz and 0.8 Hz, 1H, H-3 in furyl), 
7.37-7.15 (m, 4H, CH in Ar), 6.80 (dd, J = 3.5 Hz and 1.7 Hz, 1H, H-4 in furyl), 5.48 (s, 
2H, CH2), 2.22 (s, 3H, CH3).  
 
13C NMR (DMSO-d6, 75 MHz): δ 169.2 (CO), 159.9 (d, JCF = 246 Hz, CF in Ar), 152.8 
(C-5), 152.6 (C-2), 148.7 (C-2 in furyl), 146.3 (C-5 in furyl), 145.5 (C-8), 145.1 (C-6), 
130.3 (d, JCF = 3.4 Hz, CH in Ar), 130.1 (CH in Ar)†, 124.7 (d, JCF = 3.5 Hz, CH in Ar), 
124.3 (C-4), 123.1 (d, JCF = 14.5 Hz, C in Ar), 117.5 (C-3 in furyl), 115.4 (d, JCF  = 20.8 
Hz, CH in Ar), 112.8 (C-4 in furyl), 40.4 (CH2), 24.5 (CH3). 
MS EI m/z (rel. %): 351 (85, M+), 309 (100), 290 (6), 200 (28), 109 (97), 83 (8).  
HR-MS Found 351.1135, calcd. for C18H14FN5O2 351.1132. 
Anal.: Found C, 60.93; H, 3.45; N, 19.72. C18H14FN5O2 requires C, 61.53; H, 4.02; N, 
19.93. 
M.p.   194 ºC 
                                                            
† Signals for the CH carbon in 13C spectrum overlaps with another CH signal. It is not possible to calculate 
the coupling constant. Integration of the peak confirms that it is an overlap of signals. 
 
 
 
Spectrum 49. 1H of N-(9-(2-fluorobenzyl)-6-(furan-2-yl)-9H-purin-2-yl)acetamide (31a).  
 
Spectrum 50. 13C of N-(9-(2-fluorobenzyl)-6-(furan-2-yl)-9H-purin-2-yl)acetamide (31a). 
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Spectrum 51. HMQC of N-(9-(2-fluorobenzyl)-6-(furan-2-yl)-9H-purin-2-yl)acetamide (31a).  
 
Spectrum 52. HMBC of N-(9-(2-fluorobenzyl)-6-(furan-2-yl)-9H-purin-2-yl)acetamide (31a). 
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N-acetyl-N-(9-(2-fluorobenzyl)-6-(furan-2-yl)-9H-purin-2-yl)acetamide (31b) 
 
1H NMR (DMSO-d6, 300 MHz): δ 8.80 (s, 1H, H-8), 8.08 (dd, J = 1.7 Hz and 0.8 Hz, 1H, H-
5 in furyl), 7.92 (dd, J = 3.5 Hz and 0.8 Hz, 1H, H-3 in furyl), 7.36-7.16 (m, 4H, CH in Ar), 
6.84 (dd, J = 3.5 Hz and 1.7 Hz, 1H, H-4 in furyl), 5.58 (s, 2H, CH2), 2.17 (s, 6H, 2 × CH3). 
 
13C NMR (DMSO-d6, 75 MHz): δ 171.8 (2 × CO), 159.9 (d, JCF = 246 Hz, CF in Ar), 153.1 
(C-4), 152.4 (C-2), 148.0 (C-2 in furyl), 147.9 (C-8), 147.0 (C-5 in furyl), 145.9  (C-6), 130.4 
(d, JCF = 8.3 Hz, CH in Ar), 130.1 (d, JCF = 3.5 Hz, CH in Ar), 126.8 (C-5), 124.7 (d, JCF = 
3.5 Hz, CH in Ar), 122.8 (d, JCF = 14.5 Hz, C in Ar), 118.6 (C-3 in furyl), 115.5 (d, JCF  = 
20.8 Hz, CH in Ar), 113.1 (C-4 in furyl), 41.0 (CH2), 25.7 (2 × CH3). 
MS EI m/z (rel. %): 393 (12, M+), 351 (59), 336 (86), 309 (65), 200 (16), 109 (100), 83 (9), 
43 (18).  
HR-MS Found 393.1240, calcd. for C20H16FN5O3 393.1237.  
 Anal.: Found C, 60.78; H, 3.49; N, 17.61. C20H16FN5O3 requires C, 61.07; H, 4.10; N, 17.80. 
M.p.  178 ºC 
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Spectrum 53. 1H of N-acetyl-N-(9-(2-fluorobenzyl)-6-(furan-2-yl)-9H-purin-2-yl)acetamide (11b). 
 
Spectrum 54. 13C of N-acetyl-N-(9-(2-fluorobenzyl)-6-(furan-2-yl)-9H-purin-2-yl)acetamide (11b). 
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Spectrum 55. HMQC of N-acetyl-N-(9-(2-fluorobenzyl)-6-(furan-2-yl)-9H-purin-2-yl)acetamide  
(31b). 
 
Spectrum 56. HMBC of N-acetyl-N-(9-(2-fluorobenzyl)-6-(furan-2-yl)-9H-purin-2-yl)acetamide (31b). 
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